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Vitamin B12-associated pathologies are common, but the underlying 
mechanisms are unclear. In the cytosol, vitamin B12 functions as a required cofactor 
for methionine synthase (MTR) in the remethylation of homocysteine to methionine, 
which regenerates tetrahydrofolate (THF) for subsequent nucleotide biosyntheses. 
Impairments in this pathway are most apparent in megaloblastic anemia, which 
results from the inhibition of DNA synthesis due to the trapping of folate cofactors as 
5-methyltetrahydrofolate (5-methylTHF).  
The first objective sought to determine the impact of maternal vitamin B12 
deficiency and Shmt1 disruption on neural tube defect (NTD) incidence. Vitamin B12 
deficiency, independently of folate status, caused NTDs in Shmt1-/- and Shmt1-/+ 
embryos. Folate status and folate-deficiency in vitamin B12 deficiency did not affect 
NTD incidence. Folate, but not vitamin B12 deficiency, significantly increased plasma 
homocysteine in pregnant dams and resulted in decreased embryonic growth. Taken 
together, these findings suggest that neural tube closure is more sensitive to maternal 
vitamin B12 deficiency than homocysteine remethylation or embryonic growth.   
The second objective aimed to determine the impact of a cytosolic vitamin B12 
deficiency on nuclear de novo thymidylate (dTMP) biosynthesis, given the recent 
discovery of a nuclear, multi-protein complex for de novo synthesis of dTMP. Both 
 human fibroblasts with loss-of-function mutations in MTR and HeLa cells treated with 
nitrous oxide (N2O) gas demonstrated intracellular accumulation of 5-methylTHF 
ranging from 1.75-2.5-fold compared to control conditions. In vitamin B12 depleted 
HeLa cells, the nucleus was the most sensitive cellular compartment to 5-methylTHF 
accumulation, with a greater than 4-fold increase observed at the expense of THF. 
Vitamin B12 depletion in HeLa cells impaired rates of de novo dTMP biosynthesis and 
increased DNA damage; both outcomes were exacerbated by folate depletion. By 
contrast, MTR loss-of-function depressed rates of de novo dTMP biosynthesis, but 
did not increase DNA damage; this latter observation may be explained by the fact 
that specific tissues exhibit differential sensitivity to vitamin B12 deficiency. Taken 
together, these findings demonstrate cytosolic vitamin B12 depletion traps nuclear 
folate as 5-methylTHF, decreases rates of de novo dTMP biosynthesis, and 
increases DNA damage, providing a mechanism that can be extended to vitamin B12-
associated pathologies. 
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CHAPTER 1: IN SEARCH OF A COMMON MECHANISM UNDERLYING FOLATE-
RESPONSIVE NEURAL TUBE DEFECTS 
 
 
Introduction 
Neural tube defects (NTDs) result from improper neural tube closure, 
occurring approximately 22-28 days post conception, before a woman is aware she is 
pregnant (1). The birth prevalence is 6-60/10,000 live births worldwide and varies 
widely by ethnicity and geographic region (1, 2). Neurulation encompasses a series of 
highly regulated cellular events including proliferation, migration, and differentiation in 
the transformation and folding of the neural plate into the neural tube (3, 4). 
Disruptions to this coordinated sequence of events can result a number of structural 
defects. Anencephaly, which occurs at anterior sites of closure along the mid-
hindbrain region, is almost always incompatible with life, whereas individuals with 
spina bifida face a spectrum of life-long disabilities with varying degrees of paralysis 
that incur high social and economic costs (5).  
It has been nearly 25 years since two landmark randomized controlled trials 
(RCTs) demonstrated that maternal folic acid supplementation in the periconceptional 
period could reduce the risk of recurrence and first occurrence of an NTD by up to 
70% (6, 7). These findings led to a series of recommendations from public health 
officials in the United States (U.S.) urging women of childbearing age to consume 
400-4,000 µg folic acid daily to prevent the first occurrence or subsequent recurrence 
of an NTD-affected pregnancy (8–10). Fortification of enriched cereal grain products 
in the U.S. with 140 µg of folic acid per 100 grams product was mandated by the 
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beginning of 1998 (11). The greatest reduction in the birth prevalence of NTDs 
occurred during the period immediately following the fortification mandate in the U.S. 
(1999-2000), with the estimated annual number of NTD-affected pregnancies falling 
from 4,000 to 3,000 in the U.S. during this time (12). The success of this public health 
initiative has since led to the implementation of mandatory fortification programs in 
over 50 countries (13). Despite several decades of research, the mechanism by 
which folic acid prevents NTDs remains unknown; however, it is widely accepted that 
maternal folate supplementation does not prevent NTDs by correcting for a deficiency 
of folate as mothers with NTD-affected pregnancies do not present with an overt 
folate deficiency (14, 15). These findings are supported by the observations that 
rendering mice folate-deficient alone does not induce NTDs (16).  
Family history is another risk factor for NTDs, and the risk of spina bifida 
and/or anencephaly in siblings of NTD-affected individuals is increased by 3-8% (17). 
Furthermore, risk for NTDs varies widely by ethnicity and geographical region, 
suggesting a strong genetic component in disease pathogenesis (2, 17). The initial 
reports from epidemiological reports prompted investigators to prioritize identifying 
those variants in genes that metabolize folate; however, the genetic burden has yet to 
be identified. Therefore, the etiology of folate-responsive NTDs likely involves a 
complex interaction between genetic and environmental factors that modify disease 
risk (Figure 1), suggesting there may be a metabolic basis for folate-responsive 
NTDs. This chapter provides a review of the metabolic evidence that illustrates the 
known folate-dependent mechanisms of neural tube closure from both relevant 
human studies and animal models. 
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Figure 1.1. Conceptual schematic of neural tube defect etiology. Figure was 
amended from PJ Stover (personal communication) and inspired by Blom et al. (18). 
Image source: U.S. Centers for Disease Control and Prevention (CDC).  
 
 
Folate-mediated one-carbon metabolism is compartmentalized within the cell 
Tetrahydrofolates (THF) are a family of metabolic cofactors that carry and 
activate one-carbon units at three oxidation states: formate (10-formylTHF), 
formaldehyde (5,10-methyleneTHF), and methanol (5-methylTHF) (Fig. 2) (19). One-
carbon units are generated by the catabolism of serine, glycine, sarcosine, 
dimethylglycine, and histidine, and are required for the de novo synthesis of purines 
and methionine in the cytosol, thymidylate (dTMP) in the nucleus, and formate in the 
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mitochondria. These biosynthetic pathways comprise a metabolic network referred to 
as folate-mediated one-carbon metabolism (FOCM). The exchange of folate cofactors 
is minimal between the cytosol and mitochondria, but one-carbon donors including 
serine, glycine, and formate may freely traverse between both compartments (20). 
The concentration of folate-utilizing proteins within the cell exceeds the amount of 
available folate cofactor, thus creating competition between pathways that is 
achieved by compartmentalization, which is most apparent in the use of 5,10-
methyleneTHF for both the de novo dTMP biosynthesis and homocysteine 
remethylation pathways (Fig. 3). (21) 
Mitochondrial FOCM generates formate for the FOCM pathways in the cytosol 
and nucleus. The hydroxymethyl group of serine is transferred to THF to form 5,10-
methyleneTHF and glycine, catalyzed by SHMT2 (19). Glycine can be exported to the 
cytosol or further metabolized to 5,10-methyleneTHF via the glycine cleavage system 
(GCS). 5,10-methyleneTHF is oxidized to 10-formylTHF by the 5,10-methyleneTHF 
dehydrogenase and 5,10-methenylTHF cyclohydrolase activities of the bifunctional 
isoforms MTHFD2 or MTHFD2L (22). 10-formylTHF is oxidized in a final step by the 
10-formylTHF synthetase activities of MTHFD1L to yield THF and formate, with the 
latter product being exported to the cytosol (23–25). The mitochondrial one-carbon 
metabolic pathways also synthesize formylated methionine-tRNA for mitochondrial 
protein biosynthesis. Additionally, a recent discovery has identified a homologous 
pathway for de novo dTMP biosynthesis in mitochondria (19, 26).  
 In the cytoplasm, de novo purine biosynthesis requires 10-formylTHF for the 
synthesis of adenosine (A) and guanosine (G) nucleotides. There are no functional 
biomarkers for impaired de novo purine biosynthesis. 
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The homocysteine remethylation pathway is also present in the cytosol and 
regenerates THF and methionine from 5-methylTHF and homocysteine. 5,10-
methyleneTHF is irreversibly reduced to 5-methylTHF by MTHFR. The remethylation 
of homocysteine to methionine is accomplished by the vitamin B12-dependent enzyme 
methionine synthase (MTR) and allows for the regeneration of THF for subsequent de 
novo synthesis of nucleotides and methionine for synthesis of S-adenosylmethionine 
that is used to methylate DNA, histones, proteins, and other small molecules, 
including neurotransmitters (27). Biomarkers of impaired homocysteine remethylation 
include elevated homocysteine and decreased methylation potential, as defined by 
the [AdoMet]/[AdoHcy], which can lead to altered gene expression (28, 29).  
In the nucleus, one-carbon units are required for de novo dTMP biosynthesis. 
During S-phase of the cell cycle or in response to DNA damage, the folate-dependent 
enzymes comprising the de novo dTMP biosynthesis pathway translocate to the 
nucleus after modification by the small ubiquitin-like modifier (SUMO) protein (30, 31). 
Serine hydroxymethyltransferase (SHMT) serves as a required scaffold protein for 
thymidylate synthase (TYMS), dihydrofolate reductase (DHFR), and 
methylenetetrahydrofolate dehydrogenase (MTHFD1) that form a complex at sites of 
DNA replication and repair (32, 33), and its expression determines de novo dTMP 
capacity but does not provide the majority of one-carbon units in dTMP (34). 5,10-
methyleneTHF can be generated by the SHMT-catalyzed cleavage of serine, or 
formate derived from the mitochondria can be condensed with THF in a reaction 
catalyzed by MTHFD1 to form 5,10-methyleneTHF (34). Stable isotope tracer studies 
in MCF-7 cells indicate that MTHFD1 provides 70-90% of the one-carbon units for 
dTMP from formate, whereas SHMT provides 10-30% of one-carbon units (34). 
Previous studies demonstrated that SHMT controls the partitioning of one-carbon 
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units between methylation reactions and de novo dTMP biosynthesis, and 
preferentially supports de novo dTMP at the expense of homocysteine remethylation 
(34). However, recent studies indicate that the MTHFD1 nuclear localization explains 
this apparent partitioning of 5,10-methyleneTHF. Under conditions of folate deficiency 
or when total cellular MTHFD1 levels are limited, de novo dTMP is prioritized at the 
expense of homocysteine remethylation through enhanced MTHFD1 nuclear 
enrichment (33, 35). 5,10-methyleneTHF is both a one-carbon donor and source of 
electrons used to methylate deoxyuridylate (dUMP) to form thymidylate (dTMP) and 
dihydrofolate (DHF), in a reaction catalyzed by TYMS. Biomarkers for impaired de 
novo dTMP biosynthesis include elevated levels of uracil content in DNA (35–39) that 
can lead to the formation of single- and double-stranded breaks (DSBs) in DNA as a 
result of base excision repair (BER) (36). 
Mitochondrial folate-mediated one-carbon metabolism 
Although disruptions in FOCM in the mitochondria result in NTDs, there is 
currently no evidence to suggest that impairments in mitochondrial FOCM underlie 
folate-responsive NTDs. Recent evidence from human studies and loss-of-function 
mouse models highlights the critical importance of mitochondrial formate production 
for neural tube closure, an observation that is not surprising given that mitochondria 
provide the majority of one-carbon units for the cytosolic and nuclear FOCM 
pathways. In spite of these encouraging findings, however, none of these mouse 
models are folate-responsive. 
  7 
 
Figure 1.2. Overview of folate-mediated one-carbon metabolism. Folate-activated 
one-carbon units are required for the synthesis of formate in the mitochondria, 
purines and methionine in the cytoplasm, and thymidylate in the nucleus. 
Abbreviations: AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; 
AICAR Tfase, aminoimidazolecarboxamide ribonucleotide transformylase; AMT, 
aminomethyltransferase; DLD, dihydrolipoamide dehydrogenase; DHF, dihydrofolate; 
DHFR, dihydrofolate reductase; GAR Tfase, glycinamide ribonucleotide 
tranformylase; GCS, glycine cleavage system; GCSH, glycine cleavage system 
protein H; GLDC, glycine decarboxylase; MTHFD1, C1-tetrahydrofolate synthase 
(formyltetrahydrofolate synthetase, 5,10-methenyltetrahydrofolate cyclohydrolase, 
5,10-methylenetetrahydrofolate dehydrogenase); MTHFD1L, formyltetrahydrofolate 
synthetase; MTHFD2, MTHFD2L, methylenetetrahydrofolate 
dehydrogenase/methenyltetrahydrofolate cyclohydrolase; MTHFS, 
methenyltetrahydrofolate synthetase; MTHFR, methylenetetrahydrofolate reductase; 
MTR, methionine synthase; SHMT, serine hydroxymethyltransferase; SUMO, small 
ubiquitin-like modifier; THF, tetrahydrofolate; TYMS, thymidylate synthase. Figure 
adapted from Field et al. (33). 
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The data from human studies linking impairments in mitochondrial folate 
metabolism with NTD risk support the idea that alterations in mitochondrial formate 
production increase risk for NTDs. Exome sequencing of the GCS components in 
cohorts from the UK, Sweden, and Japan identified novel missense variants in 
aminomethyltransferase (AMT) and glycine decarboxylase (GLDC) in NTD patients 
(Fig 2.) (40). In an Irish population, increased risk for NTDs is associated with 
homozgosity for an intronic polymorphism affecting splicing efficiency in MTHFD1L 
(41). Taken together, these associations suggest that disruptions in the production of 
one-carbon units in the mitochondria may increase risk for NTDs. 
Several groups have recently demonstrated the essentiality of mitochondrially-
derived formate for proper neural tube closure using loss-of-function mouse models, 
which supports the limited findings from human populations (40, 42, 43). Momb et al. 
showed that embryos with homozygous deletion of Mthfd1L exhibit growth delay and 
develop NTDs including exencephaly and craniorachiscisis at 100% penetrance, 
ultimately resulting in embryonic lethality by E13.5 (42). Maternal supplementation 
with sodium formate significantly rescued the number of expected NTD-affected 
embryos as well as the growth delay (42). In support of these findings, maternal 
formate supplementation also rescues NTDs in curly tail (ct/ct) embryos that have 
decreased expression of Mthfd1L (43). Loss-of-function mouse models for Amt and 
Gldc, encoded by the Amt and Gldc genes that participate in the glycine cleavage 
system (GCS), also demonstrate that mitochondrial formate production is crucial for 
neural tube closure. Embryos with homozygous gene-trap mutations in Gldc and Amt 
develop NTDs at 25-29% and 87% penetrance, respectively (40, 44). The NTDs in 
GldcGT,GT can be rescued with exogenous formate (44); however it is not known if 
Amt-/- embryos respond to maternal formate supplementation (40). These findings, 
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taken together, strongly indicate that mitochondrial formate production is critical for 
neural tube closure, but that impairments in mitochondrial FOCM are not folate-
responsive and therefore likely do not underlie folate-responsive NTDs. 
Cytosolic folate-mediated one-carbon metabolic pathways 
De novo Purine Biosynthesis 
There is currently little evidence supporting the idea that impairments in folate-
dependent de novo purine biosynthesis underlie folate-responsive NTDs. 
Investigating this pathway to better understand its role in NTD pathogenesis has been 
particularly difficult as data from cross-sectional studies have not identified genetic 
variants in enzymes in de novo purine biosynthesis that are associated with NTD risk. 
Untangling the metabolic mechanisms underlying folate-dependent de novo 
purine biosynthesis in mouse models has presented a considerable challenge. Mice 
homozygous for loss-of-function gene trap alleles in Mthfs result in early embryonic 
lethality (45, 46). These observations likely reflect the essential roles of Mthfs in 
providing 10-formylTHF for de novo synthesis of purines (46). Mthfsgt/+ mouse 
embryonic fibroblasts (MEFs) revealed a 50% reduction in de novo purine 
biosynthesis capacity, as quantified by a decrease in 14C-formate incorporation into 
genomic DNA whereas de novo dTMP biosynthesis was unaffected (46). Pax3 
splotch is a folate-responsive mouse model of NTDs that gives rise to spina bifida at 
100% penetrance. There are 9 splotch alleles that result in Pax3 mutations that yield 
a range of defects with variable penetrance and severity. MEFs derived from 
Pax3Sp/Sp embryos demonstrated significant impairments in de novo purine 
biosynthesis and a non-significant trend toward impaired de novo dTMP biosynthesis, 
as evidenced by the decrease in TYMS protein observed in mutant embryos (47). 
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When Pax3 Splotch heterozygotes were crossed with Shmt1-/- and Shmt1-/+, the 
incidence and severity of NTDs was exacerbated. These findings suggest that Pax3 
may affect both de novo purine and dTMP biosyntheses. 
Homocysteine Remethylation 
There is no evidence that impairments in homocysteine remethylation underlie 
human folate responsive NTDs. The earliest findings from case-control studies 
demonstrating associations between elevated maternal plasma homocysteine and 
NTD risk (48, 49), combined with the knowledge that homocysteine can be lowered 
with folate supplementation, led to the hypothesis that impaired homocysteine 
remethylation is causal in NTD pathogenesis. To date, the common MTHFR 677 C>T 
polymorphism has shown the strongest association with NTD risk with contributions 
from both maternal and fetal alleles, but not all studies agree (18, 50). Furthermore, 
the prevalence of the TT polymorphism does not account for the NTD incidence 
observed in the population (50). The TT genotype is associated with elevated plasma 
homocysteine (51–53), reduced folate status (53, 54), and DNA hypomethylation  (55, 
56), especially under conditions of low folate status (53, 55, 56). 
Recent findings from a large-scale population-based RCT in China (57) have 
demonstrated that the TT genotype independently predicts response to folic acid 
supplementation (53). At all doses, the TT genotype was associated with lower blood 
folate and elevated homocysteine concentrations compared to the CT or CC 
genotype (TT<CT<CC), indicating that folate supplementation can overcome the low 
folate and high homocysteine observed in TT individuals (53). In support of these 
findings, a recent systematic review assessing the relationship between MTHFR 
genotype and blood folate concentrations in women of reproductive age (12-49 years) 
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demonstrated that the blood folate concentrations are consistently highest in CC 
individuals, followed by CT and TT individuals (CC > CT > TT) (54). These 
observations are likely explained by structural studies indicating that the TT 
phenotype results from loss of flavin adenine dinucleotide (FAD) cofactor that can be 
prevented with folate, and suggest that lower blood folate observed in TT individuals 
may explain the increased risk of NTDs (58). It cannot be fully discounted that the TT 
genotype increases risk for NTDs by impaired methylation or homocysteine 
accumulation; however, no mechanistic findings have demonstrated support for this 
alternative. 
There is no evidence from studies in mouse models to indicate that 
impairments in homocysteine remethylation underlie human folate-responsive NTDs. 
Germ-line deletion of both Mthfr alleles in the mouse results in a 10-fold elevation in 
plasma homocysteine, elevated in AdoHcy and/or decreased AdoMet, and global 
DNA hypomethylation, but do not develop NTDs (59) even under conditions of folate 
deficiency (60). Mice nullizygous for cystathionine beta synthase (Cbs) exhibit 
elevated plasma homocysteine but do not develop NTDs (61). Furthermore, mice with 
reduced expression of methionine synthase reductase (Mtrr) exhibit elevated plasma 
homocysteine, decreased plasma methionine, with tissue-specific alterations in 
methylation potential, but do not develop NTDs (62). MTR null mice exhibit early 
embryonic lethality (63). 
Nuclear folate-mediated one-carbon metabolic pathways 
The evidence to date strongly supports a role for impairments in folate-
dependent de novo dTMP biosynthesis in the etiology of folate-responsive NTDs. 
Although the data from cross-sectional studies have not revealed convincing 
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associations between known genetic variants in the coding regions of folate-
metabolizing enzymes comprising the de novo dTMP biosynthesis pathway and NTD 
risk (64–66), known variants do not affect enzyme activity. The strongest evidence to 
date has focused on the common polymorphism in MTHFD1, the 1958G>A variant, 
that has a homozygosity frequency of 20% in European populations and results in 
decreased 10-formylTHF synthetase activity but does not affect plasma folate status 
or homocysteine or impair nuclear localization (35, 67–69). However, the findings 
from individual studies are contradictory, as significant associations have been 
demonstrated in the Irish (69, 70) and Italian (71) but not Dutch populations (67, 72).  
A 19-base pair deletion in intron 1 of DHFR has yielded inconclusive findings 
in conferring NTD risk (73–75). No significant differences in DHFR expression have 
been detected between individuals with one or two copies of the 19-base pair deletion 
polymorphism and those wild-type individuals (73, 74). A common 28-base pair 
repeat polymorphism in the promoter enhancer region of TYMS has shown conflicting 
results between studies (76, 77). Functional analyses of the repeat polymorphism 
indicate that alleles with two copies of the repeat polymorphism (2R) have decreased 
TYMS expression compared to those alleles with three copies (3R) (78). 
Evidence demonstrating that impairments in folate-dependent de novo dTMP 
are causal in the etiology of folate-responsive NTDs 
There is substantial evidence from loss-of-function mouse models supporting 
the idea that impairments in nuclear de novo dTMP biosynthesis underlie folate-
responsive NTDs. There is a loss-of-function mouse model for Dhfr exhibiting early 
embryonic lethality. A loss of function mouse model for Tyms generated by an N-
ethyl-N-nitrosourea (ENU) mutagenesis screen that identified a T > A transversion in 
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the codon encoding amino acid 106 of TYMS causing a asparagine to lysine change 
(79). Homozygous embryos die shortly after implantation due to defects in 
gastrulation; however, heterozygous mice exhibit nearly 3-fold elevations in TYMS 
protein in liver compared to wild-type mice (79). This increase is likely explained by 
the fact that TYMS autoregulates its own translation by binding its own mRNA (79). 
Mice with genetic disruptions in Shmt1 are viable and fertile (39), and this observation 
is explained by the fact that SHMT2α is redundant with SHMT1 and contributes 25% 
to nuclear de novo dTMP biosynthesis in Shmt1-/- mice (80). Mice with reductions in 
nuclear SHMT1 exhibit elevated uracil content in DNA, whereas methylation potential 
is not impaired (37–39). 
The impact of maternal folate deficiency causes sporadic folate-responsive 
exencephaly in Shmt1-/- and Shmt1-/+ embryos at low penetrance (81–83), and 
maternal supplementation with deoxyuridine (dU) fully rescues the folate-responsive 
NTDs (83). Tracer experiments in human cells have demonstrated that exogenous 
dU is incorporated into DNA as dT, and not dU, suggesting that dU supplementation 
compensates for this impairment by accelerating dTMP biosynthesis (83). When 
Shmt1-/- and Shmt1-/+ mice were crossed with Pax3 Spotch heterozygotes, the 
incidence and severity of NTDs in offspring was exacerbated (82). PAX3 and SHMT1 
co-localize in the neural tube, and genetic disruption of either Shmt1 or Pax3 results 
in a reciprocal increase in protein of the other. This exacerbated phenotype may be 
due to the decreases in TYMS protein observed when PAX3 and SHMT1 both 
decrease (82). A different Pax3 splotch strain was shown to have impaired de novo 
dTMP biosynthesis that can be rescued with supplemental thymidine and folic acid 
(84). In support of these findings, apoptosis occurs in the developing neuroepithelium 
along the lesion of NTD-affected Pax3Sp/Sp embryos (85), and deficiency of p53 
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completely rescues the NTDs observed in Pax3Sp/Sp embryos (86). 
 Mice with reduced expression of Mthfd1 do not develop folate-responsive 
NTDs, and these observations may be explained by the observation that Mthfd1gt/+ 
mice and human fibroblasts with loss-of-function mutations in MTHFD1 demonstrate 
enhanced de novo dTMP biosynthesis at the expense of homocysteine remethylation.  
 Mthfd1gt/+ mice exhibit a 40% reduction in hepatic AdoMet concentrations, 
which is expected because formate is a major source of one-carbon units for 
methylation reactions but exhibit enhanced de novo dTMP biosynthesis, as 
evidenced by reduction of genomic uracil in liver and colon of Mthfd1gt/+ mice 
compared to Mthfd1+/+ littermates fed either a control or folate-deficient diet (33, 45). 
This enhancement in de novo dTMP biosynthesis is explained by the finding that 
during folate deficiency, both Mthfd1gt/+ and Mthfd1+/+ mice demonstrate increased 
liver nuclear localization of MTHFD1, and mouse liver nuclei are resistant to folate-
depletion compared to the cytosolic compartment (33). These findings, taken 
together, explain previous observations that 5,10-methyleneTHF is preferentially 
directed towards de novo dTMP biosynthesis under conditions of folate deficiency.  
 In support of the findings in Mthfd1gt/+ embryos, recent evidence in human 
fibroblasts from a proband with inborn errors of metabolism in MTHFD1 further 
demonstrate that folate-dependent de novo dTMP biosynthesis is prioritized at the 
expense of homocysteine remethylation (35). The fibroblasts expressing MTHFD1 
with significant reductions in cyclohydrolase and dehydrogenase activities exhibited a 
two-fold increase in MTHFD1 protein in the nucleus compared to control fibroblasts. 
Stable isotope tracer studies revealed that the MTHFD1 contributions into thymidine 
and methionine were reduced by 50% and 90%, respectively, indicating that despite 
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marked impairments in both pathways, homocysteine remethylation is still prioritized 
to a lesser degree. A 7-fold decrease in de novo dTMP capacity was observed due to 
a 4-fold increase in the salvage pathway and a 2-fold increase in TK1 levels. 
Increased nuclear localization of MTHFD1 as well as increased priority conferred to 
de novo dTMP biosynthesis was insufficient to minimize genomic uracil and DNA 
damage in proband fibroblasts (35). 
Conclusions 
In closing, the current evidence strongly argues that impairments in folate-
dependent de novo dTMP biosynthesis underlie folate-responsive NTDs. Reduced 
rates of de novo dTMP biosynthesis can lead to elevated uracil content in DNA, as 
the replicative polymerases do not discriminate between dUTP and dTTP. The 
subsequent removal of genomic uracil by repair enzymes generates single- and 
double-stranded breaks in DNA, thereby compromising genome integrity (36), 
especially at those fragile sites that may be especially sensitive to replication stress 
(87). Futile cycles of replication and repair under conditions where dTTP is limiting 
can therefore lead to cell cycle arrest and apoptosis (88). Alternatively, reduced 
replication fork stability during S-phase can result in the formation of DSBs, for 
example in the case of a fork collapse (88). Therefore, impairments in dTMP 
synthesis, specifically within those cells comprising the developing neuroepithelium 
that have a high demand for dTMP production, can lead to increased genome 
instability, decreased rates of cellular proliferation, increased cell cycle arrest, and 
ultimately apoptosis that may lead to the development of NTDs. Studies to further 
advance our understanding of this pathway and its role in NTD pathogenesis should 
consider examining the impact of additional factors that may impair nuclear de novo 
dTMP biosynthesis. It is well-known that a fraction of NTD cases are not folate-
  16 
responsive (6), and vitamin B12 is an ideal nutrient to investigate, as a maternal 
deficiency has been identified as an independent risk factor for NTDs in a number of 
small case-control studies (15, 89–92).  
 Vitamin B12 is large, water-soluble B-vitamin that consists of a central cobalt 
atom surrounded by a planar corrin ring (93). Vitamin B12 participates in FOCM as a 
required cofactor for MTR in the cytosol that remethylates homocysteine to 
methionine by using 5-methyltetrahydrofolate (5-methylTHF) and regenerates THF for 
subsequent nucleotide biosyntheses (Fig. 2). Historically, experimental models aimed 
at studying the effects of vitamin B12 deficiency in animals or cells have utilized 
nitrous oxide (N2O) gas treatment (94–97). Oxidation of the cobalt atom in the vitamin 
B12 bound to MTR leads to enzyme inactivation (98); therefore, blocking this step has 
served as a primary means of establishing experimental systems to study the 
underlying mechanisms of vitamin B12 deficiency in human health and disease. 
Deficiency of vitamin B12 can result from inadequate dietary intake or impaired 
absorption, with the latter cause accounting for the majority of deficiency cases (99). 
A clinical vitamin B12 deficiency can cause megaloblastic anemia by trapping folate 
cofactors as 5-methylTHF in the cytosol that leads to an inhibition of DNA synthesis 
(99). Furthermore, the role of vitamin B12 in maintaining genome stability is apparent 
in a number of cell types (100–104). It is understood that both the folate-dependent 
de novo dTMP biosynthesis and homocysteine remethylation pathways occur in 
separate compartments, but it is not known how a cytosolic vitamin B12 deficiency 
could impair nuclear de novo dTMP biosynthesis. These unanswered questions serve 
as the motivation for the work in Chapters 2 and 3.   
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CHAPTER 2: MATERNAL VITAMIN B12 DEFICIENCY CAUSES EXENCEPHALY IN 
A MOUSE MODEL OF FOLATE-RESPONSIVE NEURAL TUBE DEFECTS 
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Abstract: 
Background: Folic acid intake in the periconceptional period significantly reduces the 
risk of neural tube defect (NTD) occurrence and recurrence by up to 70%, and 
identification of other modifiable risk factors may further prevent NTD-affected 
pregnancies. Observational studies have shown an association between maternal 
vitamin B12 status and NTD risk in both folate-fortified and non-fortified populations. 
Vitamin B12 participates in folate-mediated one-carbon metabolism, and a vitamin B12 
deficiency causes an accumulation of cellular folate as 5-methylTHF, making folate 
cofactors unavailable for nucleotide biosyntheses. Serine hydroxymethyltransferase 
(SHMT) serves as an essential scaffold for the assembly of a nuclear multienzyme 
complex comprising the folate-dependent de novo thymidylate (dTMP) biosynthesis 
pathway enzymes; mice with reduced Shmt1 expression have elevated uracil content 
in DNA and embryos are sensitized to NTDs under conditions of maternal folate 
deficiency. Therefore, this model system is ideal for examining the role of vitamin B12 
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deficiency in NTD pathogenesis, specifically in relation to folate-dependent de novo 
dTMP biosynthesis. 
Objective: The impact of mild maternal vitamin B12 deficiency, under folate-replete 
and deficient conditions, on NTD incidence was investigated in the Shmt1 mouse 
model.  
Design: Shmt1-/- and Shmt1-/+ female mice were randomized to 1 of 4 diets: 1) 
AIN93G, 2) AIN93G - folate, 3) AIN93G - vitamin B12, and 4) AIN93G lacking vitamin 
B12 and folate for a minimum of 8 weeks. Females (12 – 24 weeks) fed the AIN93G 
diet deficient in folate and/or vitamin B12 were mated to Shmt1-/+ males, and embryos 
were examined for the presence of NTDs at E12.5. The following outcomes were also 
measured: plasma metabolites (plasma folate, vitamin B12, formate, and 
transsulfuration pathway biomarkers), the number of resorptions and implants, crown-
rump (CR) length, and embryonic Shmt1 genotype. 
Results: The vitamin B12-  and folate-deficient diets reduced mean serum vitamin B12 
and/or folate concentrations by 72 and 79%, respectively.  NTDs were observed in 
Shmt1-/- and Shmt1-/+ embryos from dams fed the vitamin B12 deficient diet. Dietary 
folate and maternal folate status did not cause a significant difference in NTD 
incidence between the vitamin B12 deficient groups. Transsulfuration pathway 
metabolites (homocysteine, cystathionine, and cysteine) were significantly predicted 
by maternal folate status but not by maternal vitamin B12 status. Maternal dietary 
folate deficiency and embryonic Shmt1 genotype, but not vitamin B12 status, predicted 
CR length.  
Conclusions: Vitamin B12 deficiency is an independent risk factor for NTDs in the 
Shmt1 mouse model, and NTDs were observed in both Shmt1-/- and Shmt1-/+. No 
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differences were observed in rates of NTDs between the vitamin B12-deficient, folate-
replete and the vitamin B12- and folate-deficient dams. Although maternal vitamin B12 
deficiency caused NTDs, it did not significantly impair growth or increase plasma 
homocysteine, indicating that neural tube closure is more sensitive to mild maternal 
vitamin B12 deficiency compared to embryonic growth and homocysteine 
remethylaton.  
Keywords: SHMT | neural tube defects | vitamin B12 | folic acid | thymidylate 
 
Introduction 
Neural tube defects (NTDs), including spina bifida and anencephaly, occur 
when the neural folds fail to fuse during early embryogenesis (1). The etiology of 
NTDs is multifactorial and involves interactions among both genetic and 
environmental factors, although the underlying mechanisms are not fully understood 
(2). The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is 
associated with NTDs in some populations due to its effect on reducing folate status 
(3–5); however, much of the genetic basis of NTDs remains unidentified. 
Maternal folic acid supplementation prevents NTD occurrence and recurrence 
(6, 7). In the period immediately following the mandatory folic acid fortification of 
enriched flour (1999-2000), the prevalence of NTDs in the US was reduced to a 
baseline rate of 0.6/1,000 live births (8, 9). However, NTD prevalence has remained 
relatively stable in the years following, as not all NTD cases are folate-responsive (9). 
Therefore, identifying the remaining non-genetic risk factors may inform new 
interventions to further reduce the incidence of NTD-affected pregnancies. Particular 
attention has focused on better understanding those risk factors that are closely 
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interrelated with folate-mediated one-carbon metabolism that may impair either folate 
status or metabolism (10–13).  
Maternal vitamin B12 deficiency is a proposed NTD risk factor. Several small 
case-control studies show an association between low maternal vitamin B12 status 
and increased risk for NTDs (14–23). In the period following mandatory folic acid 
fortification in Canada, second trimester mothers in the lowest quartile of 
holotranscobalamin (holo-TC, a biomarker of vitamin B12 status) exhibited a nearly 3-
fold greater risk for having an NTD-affected pregnancy compared to the reference 
quartile, with no difference in folate status among the groups (20, 24). In a non-folate-
fortified population, Molloy and colleagues demonstrated a 2.5 to 3-fold increase in 
NTD risk among Irish mothers with low serum vitamin B12 at 15 weeks gestation when 
comparing lowest and highest quartiles of serum vitamin B12 (19). No prospective 
studies have assessed the causal relationship between maternal vitamin B12 status 
and NTD risk in human populations nor has this question been investigated in animal 
models.  
Within the cell, folates carry and activate one-carbon units for de novo 
synthesis of nucleotides (purines and dTMP) and remethylation of homocysteine to 
methionine (25) (Fig. 2.1). Increasing evidence from both epidemiologic and animal 
studies suggests that impairments in de novo dTMP biosynthesis underlie folate-
responsive NTDs (26–28). SHMT is a required scaffold protein for other components 
of the nuclear de novo dTMP biosynthesis pathway, including TYMS, DHFR, and 
MTHFD1 (29, 30) (Fig. 2.1). In mice, Shmt1 loss-of-function leads to increased uracil 
content in DNA, but does not cause homocysteine remethylation cycle impairments 
(31). The Shmt1 mouse is the only mouse model with a genetic disruption in a gene 
encoding a folate-dependent enzyme that causes folic acid-responsive NTDs, and 
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this NTD phenotype is observed in both Shmt1 homozygotes and heterozygotes 
embryos.  This mouse model reflects the pathogenesis of folate-responsive human 
NTD cases that arise from gene by diet interactions at a low penetrance with only 
minor alterations in biomarkers of one-carbon metabolism (2, 26, 28, 32). Maternal 
dietary deoxyuridine (dU) supplementation rescues NTDs observed in Shmt1-/- and 
Shmt1-/+ embryos carried by folate-deficient dams, and tracer studies in cultured 
human cells have shown that dU is ultimately incorporated into DNA as 
deoxythymidine (dT) (28). Taken together, these findings suggest that de novo dTMP 
biosynthesis underlies folate-responsive NTDs, and that exogenous dU may prevent 
these NTDs by correcting the metabolic impairment in de novo dTMP biosynthesis.  
In support of these studies in mouse models, a subset of human fibroblast lines 
derived from terminated NTD-affected pregnancies revealed significantly impaired de 
novo thymidylate biosynthesis. This observed impairment in de novo dTMP capacity 
was not correlated with alterations in methylation cycle metabolites (27). Furthermore, 
several mouse models with impairments in homocysteine remethylation demonstrate 
elevated circulating homocysteine levels without NTDs (33–36), even under 
conditions of maternal folate deficiency (35), suggesting that this pathway is not 
causal in NTD pathogenesis.  
Vitamin B12 functions within folate-mediated one-carbon metabolism as a 
required cofactor for methionine synthase (MTR), which catalyzes the remethylation 
of homocysteine to methionine and regenerates tetrahydrofolate (THF) for nucleotide 
biosyntheses (Fig. 2.1). Impaired MTR function leads to a trapping of folate cofactors 
as 5-methylTHF within the cell and subsequent depressed rates of nucleotide 
biosynthesis and impaired methylation reactions (37–39). This consequence is most 
readily apparent in highly proliferative cell types, where there exists a substantial 
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metabolic demand for nucleotide production, and inadequate THF leads to impaired 
cell division, dTMP synthesis and DNA replication, as in the case of megaloblastic 
anemia that results from a deficiency of either vitamin B12 or folate (37, 38). 
We investigated the impact of maternal vitamin B12 deficiency on NTD 
incidence in embryos with disruptions in Shmt1 expression. Associations between 
maternal vitamin B12 deficiency and increased risk for NTDs in humans (15, 16, 18–
20), coupled with the knowledge that vitamin B12 is required to maintain de novo 
dTMP biosynthesis, prompted us to test the a priori hypothesis that a maternal B12 
deficiency sensitizes Shmt1-/- and Shmt1-/+ embryos to NTDs. Our second a priori 
comparison asked whether incidence of NTDs differed between embryos from dams 
fed a vitamin B12-deficient, folate-replete diet compared to a combined vitamin B12- 
and folate-deficient diet. The second comparison was prompted by recent findings 
from cross-sectional studies that have suggested low vitamin B12 and high folate 
status exacerbates symptoms of several common vitamin B12-associated pathologies, 
including anemia and cognition (40, 41). 
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Figure 2.1. One-carbon metabolism in the nucleus, cytosol, and mitochondria. 
Folate- and vitamin B12-mediated one-carbon metabolism is compartmentalized within 
the cell. The hydroxymethyl group of serine is a primary source of 1C units, and can 
enter the pool of activated 1C units by SHMT-catalyzed cleavage of serine. 
Otherwise, serine and glycine are converted to formate in mitochondria, which 
traverses to the cytosol and nucleus where it is condensed with THF by MTHFD1. 1C 
metabolism in the cytosol includes the de novo synthesis of purines and the 
remethylation of homocysteine to methionine. Vitamin B12 is a required cofactor for 
MTR. De novo dTMP biosynthesis occurs in the nucleus, catalyzed by the enzymes 
SHMT1, SHMT2α, TYMS, and DHFR, which undergo SUMOylation leading to 
nuclear import in S-phase. 5,10-methyleneTHF is synthesized by SHMT or MTHFD1 
for de novo dTMP synthesis. AdoHcy, S-adenosylhomocysteine; AdoMet, S-
adenosylmethionine; AICAR Tfase, aminoimidazolecarboxamide ribonucleotide 
transformylase; DHF, dihydrofolate; DHFR, dihydrofolate reductase; GAR Tfase, 
glycinamide ribonucleotide tranformylase; GCS, glycine cleavage system; MTHFD1, 
methylenetetrahydrofolate dehydrogenase 1; MTHFD1L, methylenetetrahydrofolate 
dehydrogenase 1-like; MTHFD2 & MTHFD2L, methylenetetrahydrofolate 
dehydrogenase 2 and 2-like; MTHFR, methylenetetrahydrofolate reductase; MTR, 
methionine synthase; SHMT, serine hydroxymethyltransferase; SUMO, small 
ubiquitin-like modifier; THF, tetrahydrofolate; TYMS, thymidylate synthase. Figure 
adapted from Field et al. (30). 
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Methods 
Mouse models: The Shmt1 mouse model and its sensitivity to folate deficiency in the 
etiology of NTDs has been described previously (26, 28, 32). Shmt1-/+ females were 
generated by intercrossing Shmt1-/+ breeding pairs maintained on a pure 129SvEv 
background. Shmt1-/- females were generated by intercrossing Shmt1-/- breeding pairs 
on the 129SvEv background. 
Experimental animals and diets: All animal experiments were approved by the Cornell 
Institutional Animal Care and Use Committee (Cornell University, Ithaca, NY) 
according to the guidelines of the Animal Welfare Act and all applicable federal and 
state laws. Mice were maintained on a 12-h light/dark cycle in a temperature-
controlled room. All female Shmt1-/- and Shmt1-/+ mice derived from Shmt1-/+ and 
Shmt1-/- crosses were weaned onto an AIN93G diet lacking folic acid and vitamin B12 
(Dyets, Bethlehem, PA). Weekly supplementation of vitamin B12 and/or folate 
comprised a total of 4 diet groups determined a priori: 1) AIN93G (control diet; CD), 2) 
AIN93G - folate (folate-deficient diet; FDD), 3) AIN93G - vitamin B12 (vitamin B12 
deficient diet; B12DD), 4) AIN93G – folate & vitamin B12 (combined vitamin B12 and 
folate deficient diet; B12FDD) (refer to Supplemental Information). At weaning, mice 
were randomized to one of the 4 diets, and, once weekly, were fasted overnight (12-
h). The following morning, mice were individually housed in an empty cage with 
access to water, and administered a supplement corresponding to the appropriate 
diet. Following consumption of the supplement, mice were returned to their cages; all 
mice housed within a cage were assigned to the same diet regimen. Those mice that 
failed to consume the weekly supplement in 3 consecutive weeks were removed from 
the study. All mice were maintained on these diets from weaning until sacrifice. 
Following 8 weeks on experimental dietary regime, virgin Shmt1+/- and Shmt1-/- dams 
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were mated to Shmt1+/- males overnight, and examined each morning for the 
presence of a vaginal plug to determine gestational age. Pregnant females were 
sacrificed at E12.5 by cervical dislocation. Maternal blood was collected by cardiac 
puncture, plasma and red blood cells were separated, and all samples were stored at 
-80°C. Gravid uteri were removed, and all implant and resorption sites were recorded. 
Live embryos were examined for the presence of malformations; a subset of those 
NTD-affected embryos were fixed in 10% neutral buffered formalin. Crown-rump 
length was determined and yolk sacks were collected for embryo Shmt1 genotyping. 
Genotype analysis: Genotyping for Shmt1-/-, Shmt1-/+, and Shmt1+/+ alleles was 
performed using established protocols (31). 
Determination of metabolites:  
Plasma folate: Total serum folate concentrations were quantified by the 
Lactobacillus casei microbiological assay as described previously (42).  
Serum vitamin B12: Total serum vitamin B12 was measured by a modification of 
published procedures (43). Briefly, serum was thawed on ice and diluted 10-fold in 
extraction buffer containing sodium hydroxide (8.3 mM), acetic acid (20.7 mM), and 
sodium cyanide (0.45 mM), pH 4.5 to liberate protein-bound vitamin B12 in serum. 
Samples were autoclaved for 20 minutes at 121°C, cooled on ice, and spun down for 
15 minutes at maximum speed in a tabletop centrifuge at 4°C. The supernatant was 
removed, and the extracted volume recorded. The concentration of serum vitamin B12 
in individual samples was determined using a standard curve that consisted of 1 
pg/µL, 20 pg/µL, 40 pg/µL, 60 pg/µL, and 80 pg/µL cyanocobalamin standards added 
to respective standard tubes at a final concentration of 0-80 pg as appropriate. 
Vitamin B12 Assay Media (Becton-Dickinson, #245710) was prepared according to the 
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manufacturer’s instructions. In glass borosilicate tubes, 10 mL assay mixtures were 
prepared for the following: 1) samples (B12 assay media: 5 mL, extracted plasma: 40 
µL, deionized water: 4.86 mL), 2) standards (B12 assay media: 5 mL, diluted 
cyanocobalamin in extraction buffer: 50 µL, deionized water: 4.85 mL), 3) blank (B12 
assay media: 5 mL, extraction buffer: 40 µL, deionized water: 4.86 mL), and 4) zero 
standard (B12 assay media: 5 mL, extraction buffer: 40 µL, deionized water: 4.86 mL). 
The tubes containing assay mixtures were autoclaved for 20 minutes at 121°C and 
allowed to cool to room temperature before inoculation with 100 µL of either 0.9% 
saline (blank) or L. leischmanii diluted 1:50 in 0.9% saline (zero, standards, samples). 
Cultures were incubated at 37°C for 18 hours. The following day, tubes were vortexed 
and subsequently plated in triplicate into 96-well plates (300 µL/well), that included a 
standard curve on each plate. All plates were read at 595 nm on a Gen5 microplate 
reader (BioTek). One standard curve was constructed by averaging the standard 
curve readings from all plates, and the vitamin B12 concentrations in the extracted 
samples were determined from this single curve. 
Plasma formate: Plasma formate was quantified in a subset of samples (n=10 dams 
comprising a mixture of both Shmt1-/- and Shmt1-/+ genotypes) from pregnant study 
dams from each of the 4 diet groups as described previously (Table 2.4) (44).  
Plasma homocysteine panel: Plasma homocysteine, cystathionine, cysteine, 
methionine, glycine, serine, and α-aminobutyric acid metabolites were quantified in a 
subset of samples (n=10) from pregnant study dams in each of the 4 diets as 
described previously (45, 46). Each diet contained a subset of both Shmt1-/- and 
Shmt1-/+ genotypes (Table 2.4). 
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Statistical analyses: 
Plasma metabolites: Analyses of plasma metabolites were assessed using a two-
way analysis of variance (ANOVA) with Tukey’s honestly significant difference (HSD) 
test for post-hoc analysis. Independent variables included maternal Shmt1 genotype, 
maternal diet, as well as the interaction between genotype and diet. If the interaction 
term was not significant, it was removed, and the model was fit again to test the main 
effects of maternal diet and genotype. Metabolites with non-normal distributions were 
either log- or rank-transformed to improve the normal distribution assumption. Linear 
contrasts were used to assess the influence of individual nutrients (e.g., vitamin B12) 
on metabolite response in the case of plasma [serine]/[glycine].  
NTDs: Fisher’s exact test for independence with Bonferroni’s correction (n=2) was 
used to assess the following comparisons for NTD incidence from dams fed the 
B12DD compared to that from dams fed the: 1) CD and 2) B12FDD. Because we did 
not expect the rates of NTDs in offspring from vitamin B12 deficient dams to be less 
than the rates of NTDs for offspring from the CD, a one-sided Fisher’s Exact Test was 
used to assess the impact of maternal vitamin B12 deficiency versus the CD. The 
impact of embryonic Shmt1 genotype on NTD incidence was assessed using exact 
tests.  
Crown-rump length: Mixed models evaluated the fixed effects of maternal Shmt1 
genotype, embryonic Shmt1 genotype, maternal diet, and two relevant interaction 
terms, namely, maternal genotype x diet and embryonic genotype x diet on crown-
rump (CR) length. Litter was included in the model and treated as a random effect. 
The interaction term was removed from the model when it was not significant and 
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main effects were tested again. A Tukey’s HSD test for post-hoc analysis was used to 
assess differences when main effects were significant.  
Resorptions: Generalized estimating equations models were used to evaluate the 
fixed effects of maternal Shmt1 genotype, maternal diet, and the interaction between 
genotype and diet on the odds of resorption for all implanted embryos. These models 
assumed binomial errors and used a logit link function. Implants were considered 
repeated measures within litter. Differences in observed versus expected embryonic 
genotype distributions in litters from Shmt1-/- and Shmt1-/+ dams were analyzed by a 
Chi-Square test.  
 
Results 
Supplemented diets modulate plasma folate and vitamin B12 in study dams 
Plasma folate concentrations were influenced by Shmt1 disruption (F = 10.02, 
p = 0.002; Table 2.1) and dietary folate deficiency (F = 166, p< 0.0001). The 
interaction between both diet and genotype was significant (F = 4.78; p = 0.003; 
Table 2.1). The mean plasma folate concentrations in dams fed the folate deficient 
diets (FDD and B12FDD) were reduced by approximately 79% compared to the mean 
serum folate concentrations in dams fed the folate-replete diets (B12DD and CD) 
(Table 2.1). Serum vitamin B12 concentrations were influenced by maternal Shmt1 
genotype (F = 23.7; p<0.0001) and a dietary vitamin B12 deficiency (F = 129.3; 
p<0.0001; Table 2.1). There was a significant interaction between Shmt1 genotype 
and maternal diet (F = 3.37; p = 0.02). Both vitamin B12 deficient diets (B12DD and 
B12FDD) were significantly different from the vitamin B12-replete (CD and FDD) diets 
(p<0.0001). Dietary maternal vitamin B12 deficiency reduced mean serum vitamin B12 
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concentrations by 72% when comparing the vitamin B12 replete (CD and FDD) and 
deficient (B12DD and B12FDD) diet groups.  
Vitamin B12 deficiency causes NTDs in Shmt1-/- and Shmt1-/+ embryos 
Maternal diet was significant at the litter level (p = 0.01). Maternal vitamin B12 
deficiency significantly predicted NTD risk compared to the CD (p = 0.008). There 
was no difference in the rates of NTDs between the B12DD and the B12FDD groups (p 
> 0.05). Embryonic genotype significantly predicted NTD response (p = 0.001), and 
deletion of both Shmt1 alleles significantly increased NTD risk compared to Shmt1-/+ 
(p = 0.004) and Shmt1+/+ (p=0.005) embryos (Table 2.3). Maternal Shmt1 genotype 
did not significantly influence NTD incidence (p > 0.05), which is consistent with 
previous observations. Therefore, all maternal genotypes within individual diets were 
combined for further analyses. 
 
Crown-rump length and resorptions  
Maternal diet (F= 5.42; p = 0.0013) and embryonic Shmt1 genotype (F= 4.77; 
p=0.0087) significantly predicted embryonic CR length but maternal Shmt1 genotype 
did not (p > 0.05) (Table 2.2). There was no significant interaction detected for either 
maternal Shmt1 genotype and diet (p > 0.05) or embryonic Shmt1 genotype and diet 
(p > 0.05). Embryos from dams consuming folate deficient diets (FDD and B12FDD) 
were significantly smaller compared to those from to dams fed the B12DD, indicating 
that maternal folate deficiency is likely responsible for the observed growth restriction. 
Shmt1-/- embryos were significantly smaller compared to Shmt1-/+ and Shmt1+/+ 
embryos. Neither maternal genotype nor diet had a significant effect on rates of 
resorption (p > 0.05). There were no differences between the observed and expected 
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embryonic genotypes in litters from Shmt1-/- and Shmt1-/+ dams (p = 0.47 and p = 
0.71, respectively, chi-square test). 
Maternal dietary folate deficiency influences plasma transsulfuration pathway 
metabolites 
Plasma concentrations of transsulfuration pathway metabolites were 
influenced by dietary folate deficiency, but not maternal Shmt1 genotype. The 
interaction term between maternal genotype and diet was not significant (p>0.05). 
Maternal folate deficiency increased plasma homocysteine concentrations, with 
significant differences observed between the folate-deficient (FDD and B12FDD) and 
replete (CD and B12DD) diets (F = 21.97; p<0.0001 (Table 2.4). Plasma cystathionine 
was significantly influenced by maternal diet (F = 6.49, p = 0.0014) with significant 
decreases observed in the folate-deficient diets (B12FDD and FDD) compared to the 
CD (Table 2.4). Maternal folate deficiency also predicted plasma cysteine 
concentrations with decreases observed in the FDD compared to the B12DD and CD 
(F = 4.18, p = 0.013). Plasma concentrations of methionine, α-aminobutryic acid, 
serine, glycine, or the ratio of serine-to-glycine ([serine]/[glycine]) were not influenced 
by either maternal diet or Shmt1 genotype (p>0.05; Table 2.4), but a linear contrast 
performed between the vitamin B12-deficient (B12FDD and B12DD) and replete (FDD 
and CD) diets revealed significant differences in the plasma [serine]/[glycine] ratio (F 
= 4.56, p=0.04). The mean ratio of [serine]/[glycine] in plasma increased by 
approximately 25% under conditions of maternal vitamin B12 deficiency (Table 2.4).  
Maternal dietary vitamin B12 deficiency influences plasma formate concentrations 
Plasma formate concentrations in pregnant study dams were significantly 
influenced by both maternal diet (F = 7.36, p = 0.01; Table 2.4) and Shmt1 genotype 
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(F = 4.48, p = 0.009); however, no significant interaction between maternal genotype 
and diet was detected (p>0.05). Plasma formate concentrations in dams from the 
B12DD were significantly different from those in the FDD and CD. Plasma formate in 
Shmt1-/+ dams on the B12DD was reduced by one-third compared to those in Shmt1-/- 
dams. 
 
 
 
Figure 2.2. Neural tube defects in Shmt1-deficient embryos at gestational day 12.5 
(E12.5). (A) Representative unaffected Shmt1-/+ embryo and (B) Shmt1-/- littermate 
that exhibited failure of rostral neural tube closure both from a Shmt1-/+ dam fed a 
vitamin B12-deficient diet. Arrows indicate location of lesion. 
A. B. 
  40 
Table 2.1. E
ffects of m
aternal diet on plasm
a folate and vitam
in B
12  concentrations by m
aternal S
hm
t1 genotype. 1 
D
iet and M
aternal G
enotype 
 
n 
Folate, ng/m
L 
Ln (Folate) 2,3,4 
n 
Vitam
in B
12 , pg/µL 
Ln (B
12 ) 5,6,7 
C
ontrol (C
D
) 
(n=68) 
50 
28.74 (1.45) 
3.29 (0.05) 
59 
7.29 (0.45) 
1.88 (0.06) 
 
S
hm
t1
+/-  
35 
28.82 (1.66) 
3.30 (0.06) 
43 
7.11 (0.58) 
1.84 (0.08) 
 
S
hm
t1
-/-  
15 
28.58 (3.01) 
3.26 (0.12) 
16 
7.76 (0.61) 
2.00 (0.08) 
V
itam
in B
12 D
eficient  (B
12 D
D
) 
(n=69) 
60 
31.96 (1.60) 
3.37 (0.06) 
63 
2.38 (0.12) 
0.80 (0.05) 
 
S
hm
t1
+/-  
46 
31.67 (1.86) 
3.35 (0.08) 
48 
2.33 (0.14) 
0.77 (0.05) 
 
S
hm
t1
-/-  
14 
32.94 (3.26) 
3.43 (0.10) 
15 
2.56 (0.26) 
0.87 (0.10) 
Folate D
eficient (FD
D
) 
(n=64) 
56 
5.99 (0.42) 
1.65 (0.07) 
57 
10.32 (0.63) 
2.21 (0.07) 
 
S
hm
t1
+/- 
44 
6.40 (0.47) 
1.74 (0.08) 
45 
9.64 (0.70) 
2.13 (0.08) 
 
S
hm
t1
-/-  
12 
4.51 (0.76) 
1.33 (0.18) 
12 
12.88 (1.26) 
2.50 (0.11) 
Folate and B
12 D
eficient (B
12 FD
D
) (n=68) 
65 
6.92 (0.46) 
1.75 (0.08) 
68 
2.60 (0.12) 
0.88 (0.05) 
 
S
hm
t1
+/- 
46 
7.90 (0.53) 
1.94 (0.08) 
48 
2.15 (0.11) 
0.71 (0.05) 
 
S
hm
t1
-/-  
19 
4.56 (0.64) 
1.30 (0.17) 
20 
3.67 (0.14) 
1.29 (0.04) 
1 V
alues are show
n as m
eans (S
.E
.). A
 tw
o-w
ay A
N
O
V
A
 assessed the effects of m
aternal S
hm
t1 genotype, m
aternal diet, and the 
interaction betw
een genotype and diet on log-transform
ed values for serum
 folate and vitam
in B
12 . P
ost-hoc com
parisons w
ere 
analyzed using a Tukey’s honestly significant difference (H
S
D
) test. 
2 S
hm
t1
-/- w
as different from
 S
hm
t1
-/+ (p = 0.002) 
3 The FD
D
 and B
12 FD
D
 w
ere significantly different from
 the C
D
 and B
12 D
D
 (p<0.0001). 
4 S
hm
t1
-/+ w
as different from
 S
hm
t1
-/- for the B
12 FD
D
 only (p = 0.003). 
5 S
hm
t1
-/- w
as different from
 S
hm
t1
-/+ (p<0.0001)  
6 The FD
D
 and C
D
 w
ere significantly different from
 the B
12 FD
D
 and B
12 D
D
 (p<0.0001).  
7 S
hm
t1
-/- w
as different from
 S
hm
t1
-/+ in the B
12 FD
D
 only (p = 0.02). 
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Table 2.2. A
verage em
bryonic crow
n-rum
p (C
R
) length, average resorption rate, average litter size, and percent N
TD
s as a 
function of m
aternal S
hm
t1 genotype and diet. 1 
D
iet and M
aternal G
enotype 
Litters, n 
Im
plants, 
n 
Litter Size  
Em
bryos, n 
N
TD
s
2, n (%
) 
R
esorptions
3, n (%
) 
C
R
 Length
4, m
m
 
C
ontrol (C
D
) 5                                  68 
445 
6.5 ± 0.3 
314 
0 (0.0) 
131 (29.4) 
8.24 ± 0.04 (292) 
 
S
hm
t1
+/-  
46 
299 
6.5 ± 0.3 
220 
0 (0.0) 
79 (26.4) 
8.32 ± 0.05 (198) 
 
S
hm
t1
-/-  
22 
146 
6.6 ± 0.5 
94 
0 (0.0) 
52 (35.6) 
8.07 ± 0.07 (94) 
V
itam
in B
12 D
eficient  (B
12 D
D
)      69
 
475 
6.9 ± 0.2 
338 
4 (1.2) 
137 (28.8) 
8.39 ± 0.04 (272) 
 
S
hm
t1
+/-  
54 
369 
6.8 ± 0.2 
260 
3 (1.2) 
109 (29.5) 
8.34 ± 0.05 (195) 
 
S
hm
t1
-/-  
15 
106 
7.1 ± 0.5 
78 
1 (1.3) 
28 (26.4) 
8.54 ± 0.09 (77) 
Folate D
eficient (FD
D
)                    64
 
403 
6.3 ± 0.3 
251 
9 (3.6) 
152 (37.7) 
7.98 ± 0.06 (208) 
 
S
hm
t1
+/- 
50 
317 
6.3 ± 0.3 
194 
6 (3.1) 
123 (38.8) 
8.02 ± 0.07 (152) 
 
S
hm
t1
-/-  
14 
86 
6.1 ± 0.7 
57 
3 (5.3) 
29 (33.7) 
7.86 ± 0.12 (56) 
Fol. and B
12  D
eficient (B
12 FD
D
)  68
 
481 
7.1 ± 0.2 
318 
4 (1.3) 
163 (33.9) 
7.91 ± 0.05 (262) 
 
S
hm
t1
+/- 
48 
350 
7.3 ± 0.3 
226 
1 (0.4) 
124 (35.4) 
7.97 ± 0.06 (170) 
 
S
hm
t1
-/-  
20 
131 
6.6 ± 0.4 
92 
3 (3.3) 
39 (29.8) 
7.80 ± 0.09 (92) 
1 M
ean ± standard error of m
ean (S
.E
.) 
2 P
ercent of em
bryos. The difference in rates of N
TD
s betw
een the C
D
 and B
12 D
D
 w
as significant (p=0.008; B
onferroni-corrected). 
There w
as no difference in N
TD
 rates betw
een the B
12 D
D
 and B
12 FD
D
 (p>0.05; B
onferroni-corrected). 
3 P
ercent of resorptions is determ
ined by dividing the num
ber of resorbed em
bryos by the total num
ber of im
plant sites (num
ber of 
live em
bryos and resorbed em
bryos). M
aternal S
hm
t1 genotype, diet, and the genotype by diet interaction did not significantly 
predict rates of resorptions (p>0.05). 
4 M
ean ± S
.E
. (n w
ith m
easured length available). M
aternal diet (p=0.0013) and em
bryonic genotype (p=0.0087) had a significant 
effect on C
R
 length, and the interaction term
s w
ere not significant (p>0.05). M
aternal genotype (p>0.05) w
as not significant. The 
folate-deficient diets (FD
D
 and B
12 FD
D
) w
ere sm
aller than the B
12 D
D
. S
hm
t1
-/- em
bryos w
ere sm
aller than S
hm
t1
-/+ and S
hm
t1
+/+ 
em
bryos. 
5 R
ates of N
TD
s w
ere determ
ined from
 a total of 200 dam
s fed the C
D
. A
 subset of these litters (n=68) w
as used in the analyses. 
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Table 2.3. Frequency of N
TD
s as a function of em
bryonic S
hm
t1 genotype. 1 
 
Em
bryo Shm
t1
+/+ 
Em
bryo Shm
t1
+/- 
Em
bryo Shm
t1
-/- 
D
iet and M
aternal G
enotype
2 
N
TD
s, n (%
) 
Em
bryos, n 
N
TD
s, n (%
) 
Em
bryos, n 
N
TD
s, n (%
) 
Em
bryos, n 
C
ontrol (C
D
) 
0 
54 
0 
154 
0 
101 
 
S
hm
t1
+/-  
0 
54 
0 
109 
0 
52 
 
S
hm
t1
-/-  
̶ 
̶ 
0 
45 
0 
49 
V
itam
in B
12  D
eficient  (B
12 D
D
) 
0 
62 
2 (1.34) 
149 
2 (1.89) 
106 
 
S
hm
t1
+/-  
0 
62 
1 (0.88) 
113 
2 (3.13) 
64 
 
S
hm
t1
-/-  
̶ 
̶ 
1 (2.78) 
36 
0 
42 
Folate D
eficient (FD
D
) 
0 
43 
2 (1.55) 
129 
6 (8.81) 
73 
 
S
hm
t1
+/- 
0 
43 
2 (2.00) 
100 
3 (6.66) 
45 
 
S
hm
t1
-/-  
̶ 
̶ 
0 
29 
3 (10.71) 
28 
Folate and B
12  D
eficient (B
12 FD
D
) 
0 
55 
0 
167 
4 (4.21) 
95 
 
S
hm
t1
+/- 
0 
55 
0 
123 
1 (2.13) 
47 
 
S
hm
t1
-/-  
̶ 
̶ 
0 
44 
3 (6.25) 
48 
1 The effect of overall em
bryonic S
hm
t1 genotype on N
TD
 incidence w
as significant p=0.0009. S
hm
t1
-/- em
bryos w
ere significantly 
different from
 S
hm
t1
-/+ (p=0.004) and S
hm
t1
+/+ em
bryos (p=0.005) as determ
ined by exact tests. 
2 M
aternal S
hm
t1 genotype did not predict rates of N
TD
s (p>0.05). 
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Table 2.4. Concentrations of plasma metabolites in pregnant Shmt1-/- and Shmt1-/+ 
dams at E12.5 fed a control, folate-deficient, combined vitamin B12 & folate deficient, 
or vitamin B12-deficient diet.1  
 
 
Metabolite  
 
Maternal 
Genotype 
           Diet 
 
CD 
 
FDD 
 
B12DD 
 
B12FDD 
 
HCYS2,5 (µmol/L) 
Total 
Shmt1+/- 
Shmt1-/- 
8.1 ± 0.8 
7.6 ± 1.6 
8.3 ± 0.9 
21.7 ± 3.5 
22.4 ± 4.2 
19.2 ± 7.1 
 
8.0 ± 0.7 
9.0 ± 0.9 
6.4 ± 0.8 
21.2 ± 1.5 
22.7 ± 2.2 
19.5 ± 2.0 
 
CYSTAT2,6 
(nmol/L/) 
 
 
Total 
Shmt1+/- 
Shmt1-/- 
1151 ± 108 
1104 ± 79 
1175 ± 39 
 
1800 ± 218 
1738 ± 235 
2046 ± 727 
 
1343 ± 134 
1256 ± 67 
1475 ± 338 
 
2042 ± 240 
2297 ± 347 
1658 ± 224 
  
CYS7 (µmol/L) 
 
 
Total 
Shmt1+/- 
Shmt1-/- 
187.1 ± 6.0 
177.3 ± 8.5 
191.3 ± 7.5 
 
160.2 ± 7.2 
161.8 ± 8.9 
154.0 ± 7.0 
 
184.2 ± 5.1 
193.5 ± 4.7 
170.3 ± 5.6 
 
174.2 ± 6.8 
178.7 ± 10.9 
167.5 ± 4.8 
  
ABUT4 (µmol/L) 
 
Total 
Shmt1+/- 
Shmt1-/- 
8.5 ± 0.4 
7.8 ± 0.8 
8.8 ± 0.4 
 
9.1 ± 0.5 
9.0 ± 0.7 
9.6 ± 0.5 
 
9.4 ± 0.5 
9.6 ± 0.3 
9.0 ± 1.2 
 
9.0 ± 0.3 
9.2 ± 0.4 
8.7 ± 0.5 
  
MET4 (µmol/L) 
 
Total 
Shmt1+/- 
Shmt1-/- 
56.6 ± 3.7 
60.9 ± 9.2 
54.8 ± 4.0 
 
53.0 ± 3.5 
50.6 ± 3.7 
62.3 ± 7.6 
 
61.2 ± 3.8 
59.3 ± 4.5 
64.0 ± 7.1 
 
61.6 ± 5.9 
64.3 ± 8.8 
57.7 ± 7.5 
  
GLY3,4 (µmol/L) 
 
 
Total 
Shmt1+/- 
Shmt1-/- 
102.1 ± 11.3 
100.0 ± 9.6 
103.0 ± 16.1 
 
107.1 ± 12.7 
105.0 ± 13.6 
115.6 ± 44.5 
 
89.6 ± 8.8 
84.3 ± 10.8 
97.5 ± 16.2 
 
97.7 ± 9.1 
101.0 ± 15.1 
92.8 ± 5.4 
  
SER4 (µmol/L) 
 
Total 
Shmt1+/- 
Shmt1-/- 
168.7 ± 16.6 
144.0 ± 8.7 
179.3 ± 22.7 
182.6 ± 13.0 
176.6 ± 15.7 
206.5 ± 0.5 
 
177.0 ± 14.0 
166.8 ± 11.7 
192.3 ± 31.4 
 
207.9 ± 15.1 
213.7 ± 20.1 
199.3 ± 25.8 
 
[SER]/[GLY]4,8 
 
Total 
Shmt1+/- 
Shmt1-/- 
1.70 ± 0.11 
1.46 ± 0.10 
1.80 ± 0.14 
1.85 ± 0.19 
1.79 ± 0.19 
2.10 ± 0.81 
2.14 ± 0.23 
2.14 ± 0.28 
2.14 ± 0.46 
2.28 ± 0.25 
2.34 ± 0.37 
2.19 ± 0.35 
 
FORMATE9,10 
(µmol/L) 
Total 
Shmt1+/- 
Shmt1-/- 
203.5 ± 22.1 
191.3 ± 36.9 
221.9 ± 7.9 
196.6 ± 11.6 
196.2 ± 13.7 
198.5 ± 27.9 
140.9 ± 12.7 
122.2 ± 8.9 
184.4 ± 22.9 
162.4 ± 16.1 
123.4 ± 20.3 
193.5 ± 12.1 
Abbreviations: HCYS, homocysteine; CYSTAT, cystathionine; CYS, cysteine; ABUT, 
α-aminobutyric acid; MET, methionine; GLY, glycine; SER, serine; [SER/GLY], 
serine/glycine; CD, control diet; FDD, folate-deficient diet; B12FDD, vitamin B12- and 
folate-deficient diet; B12DD, vitamin B12-deficient diet; E, embryonic day.  
1 All values are shown as means ± S.E. n=10 samples per diet group were analyzed 
for plasma metabolites. For plasma formate, the number of dams within each diet is 
as follows: CD (n=4 Shmt1-/-, n=6 Shmt1-/+), FDD (n=2 Shmt1-/-, n=8 Shmt1-/+), B12DD 
(n=3 Shmt1-/-, n=7 Shmt1-/+), B12FDD (n=5 Shmt1-/-, n=4 Shmt1-/+). For all other 
metabolites: CD (n=7 Shmt1-/-, n= 3 Shmt1-/+), FDD (n=2 Shmt1-/-, n=8 Shmt1-/+), 
B12DD (n=4 Shmt1-/-, n=6 Shmt1-/+), B12FDD (n=4 Shmt1-/-, n=6 Shmt1-/+). 
Independent effects of maternal Shmt1 genotype, diet, and the interaction between 
genotype and diet were assessed using a two-way ANOVA and a Tukey’s HSD test 
for post-hoc analysis. 
2 Metabolite values were log-transformed to improve the normal distribution 
assumption of the model. Values displayed are the non-transformed means ± S.E. 
3 Metabolite values were rank-tranformed to improve the normal distribution 
assumption of the model. Values are displayed as the non-transformed means ± S.E. 
4 There was no significant effect of Shmt1 genotype, diet, or genotype x diet 
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interaction detected. 
5 The FDD and B12FDD were significantly different from the CD and B12DD 
(p<0.0001). 
6 The B12FDD and FDD were significantly different from the CD (p = 0.0014).  
7 The FDD differed significantly from the CD and B12DD (p = 0.013). 
8 No significant effect of maternal diet on log[serine/glycine] was detected. A linear 
contrast made between vitamin B12-deficient (B12FDD + B12DD) and replete (FDD + 
CD) diets revealed significant differences in log[serine/glycine] (p = 0.04).  
9 Shmt1-/- was significantly different from Shmt1-/+ (p = 0.009) 
10 The B12DD was significantly different from the FDD and CD (p = 0.01). 
 
 
Discussion 
There exists a need to identify additional risk factors for NTDs, as folic acid 
has not reduced the birth prevalence of NTDs below an incidence of 0.6/1,000 live 
births in the post-fortification era, equating to an estimated 2,600 NTD-affected 
pregnancies in the U.S annually (9). Maternal vitamin B12 deficiency has emerged as 
a highly attractive candidate risk factor given its participation in folate metabolism as 
well as the findings from cross-sectional studies that demonstrate association 
between maternal deficiency and NTD risk (14–23). In spite of this knowledge, no 
prospective studies have assessed the role of maternal vitamin B12 deficiency in 
conferring NTD risk. Additional concerns raised in the period following mandatory folic 
acid fortification suggest that high folate status and vitamin B12 deficiency may be 
detrimental for some clinical outcomes (40, 41). No mechanistic understanding exists 
to explain this concern, nor has the vitamin B12-folate interrelationship been 
systematically examined.  
In this study, we demonstrate that maternal vitamin B12 deficiency is an 
independent risk factor for NTDs in embryos with reduced Shmt1 expression (Table 
2.2, Fig. 2.2). Interestingly, maternal vitamin B12 deficiency did not affect CR length 
(Table 2.2) or levels of plasma transsulfuration pathway metabolites (Table 2.4), but 
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did significantly predict rates of NTDs (Table 2.2), suggesting that the developing 
neuroepithelium is the most sensitive to vitamin B12 deficiency. The fact that plasma 
homocysteine was not predicted by maternal vitamin B12 deficiency suggests a 
marked, but not severe, deficiency of vitamin B12 (Table 2.4). Only two case-control 
studies demonstrating a significant association between maternal vitamin B12 
deficiency and NTD risk, independently of folate status, include plasma homocysteine 
measurements (15, 16). One study showed that maternal vitamin B12 deficiency did 
not significantly modulate plasma homocysteine levels (16) whereas the second one 
did (15).  
The incidence of NTDs between the two vitamin B12-deficient diets was not 
different (p>0.05; Table 2.2), indicating that dietary folate repletion does not 
exacerbate symptoms of disease pathogenesis in vitamin B12 deficiency, and 
therefore addresses post-folic-acid-fortification concerns regarding effects of elevated 
folate intakes and low vitamin B12 status. Additional clinical implications emerge from 
these findings, as folic acid supplementation did not affect incidence of NTDs in 
vitamin B12 deficiency (Table 2.2).  Folic acid has been proposed to compensate for 
vitamin B12 deficiency, as elevated intakes of folic acid can mask symptoms of vitamin 
B12 deficiency by overcoming impairments in de novo dTMP biosynthesis in vitamin 
B12-deficient hematopoietic cells, as is observed in megaloblastic anemia, but not in 
the central nervous system (CNS) (38, 47). Our findings that supplemental folic acid 
did not rescue NTDs in vitamin B12 deficiency suggests that folic acid intake cannot 
compensate for vitamin B12 deficiency in the neuroepithelium, similar to what is 
observed in vitamin B12-associated neuropathies (38). 
This study demonstrates that maternal vitamin B12 deficiency sensitizes 
embryos with reductions in Shmt1 expression to NTDs that could not be rescued by 
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folic acid. Therefore, these findings illustrate the need to investigate the mechanism 
by which vitamin B12 and folate interact in nuclear de novo dTMP biosynthesis, given 
that specific cell types, including hematopoietic cells and CNS tissue, differentially 
respond to vitamin B12-deficiency. This need is further supported by the conflicting 
observations suggesting that supplemental folic acid can either correct or exacerbate 
metabolic impairments in vitamin B12 deficiency. The vitamin B12-dependent 
homocysteine remethylation and de novo dTMP biosynthesis are compartmentalized 
in the cytosol and nucleus, respectively, and it is not known how the former impacts 
nuclear one-carbon metabolism for dTMP synthesis. The finding that maternal vitamin 
B12 deficiency caused NTDs but did not influence plasma homocysteine levels 
suggests that the nuclear compartment may exhibit increased sensitivity to the 5-
methylTHF trap. Lastly, these findings emphasize the need to consider fortification as 
an opportunity to reduce those vitamin B12-responsive NTDs that cannot be rescued 
with supplemental folic acid (52). Future large-scale, population-based studies 
designed to investigate the effect of periconceptional vitamin B12 supplementation 
may result in the development of efficacious interventions to further reduce NTD 
incidence.  
Contributions: AMP collected primary data. SPS & RHA provided metabolite 
measurements for plasma homocysteine panel (Table 2.4); MEB & JTB provided 
metabolite measurements for plasma formate (Table 2.4). AMP performed statistical 
analyses; JLF performed analyses for resorptions.(Table 2.2). 
Supplemental Information 
Formulation of one-carbon and vitamin B12 weekly supplements: Formulation of one-
carbon & vitamin B12 fortified mini-marshmallows: Commercially made mini-
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marshmallows (Kraft™) were fortified with the following pure compounds obtained 
from Sigma-Aldrich: vitamin B12 (cyanocobalamin), folic acid, or 2% ascorbate 
depending on the dietary scheme. Mini-marshmallows were selected as a vehicle for 
delivering the weekly dietary supplements, as they do not contain B-vitamins that 
would interfere with biomarker readouts according to the most recent Food 
Composition Tables from the U.S. Department of Agriculture. Furthermore, we used 
the L. casei assay to establish that marshmallows are folate-free (data not shown). 
The concentration of individual compounds were determined and diluted 1:1 in a 4% 
ascorbate solution. The final solution in 2% ascorbate was filtered under sterile 
conditions and injected into marshmallows to deliver 0.7 micrograms of 
cyanocobalamin and 56 micrograms of folic acid in 5 microliters of 2% ascorbate 
solution prior to storage at -80°C. These weekly supplements of dietary 
cyanocobalamin, folic acid, and 2% ascorbate added to the marshmallows were 
determined based on the composition of these vitamin and one-carbon sources in the 
AIN93G diet as well as unpublished data from our laboratory that have determined 
the amount of food (grams)/week an individual mouse consumes. Following 
preparation, the fortified marshmallows were treated with 5-20 kilograys (kGy) of 
gamma irradiation, the same range and value of gamma irradiation used to treat our 
commercially prepared diets at an offsite facility to be in agreement with Cornell 
IACUC protocols. This route of administration was preferred over gavage or 
intraperitoneal (IP) injection of aforementioned compounds as it minimizes stress to 
the animal and represents a more realistic dietary scenario. We determined, using 
established methods in our laboratory, that gamma ray treatment does not degrade 
the injected compounds. Dams in the control diet (CD) group received a weekly 
supplement containing both cyanocobalamin and folic acid. Dams in the combined 
  48 
vitamin B12 and folate deficient diet (B12FDD) group received a weekly supplement 
containing 2% ascorbate. Dams in the folate-deficient diet (FDD) or vitamin B12 
deficient diet (B12DD) groups received supplements containing cyanocobalamin or 
folic acid, respectively. 
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CHAPTER 3: FOLATE AND VITAMIN B12 INTERACT IN NUCLEAR FOLATE 
METABOLISM LEADING TO GENOME INSTABILITY 
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Abstract:  
Clinical vitamin B12 deficiency can result in megaloblastic anemia, which 
results from the inhibition of DNA synthesis by trapping folate cofactors in the form of 
5-methyltetrahydrofolate (5-methylTHF) and subsequent inhibition of de novo 
thymidylate (dTMP) biosynthesis. In the cytosol, vitamin B12 functions in the 
remethylation of homocysteine to methionine, which regenerates tetrahydrofolate 
(THF) from 5-methylTHF. In the nucleus, THF is required for de novo dTMP 
biosynthesis, but it is not understood how 5-methylTHF accumulation in the cytosol 
impairs nuclear dTMP biosynthesis. The impact of vitamin B12 depletion on nuclear de 
novo dTMP biosynthesis was investigated in methionine synthase (MTR)-null human 
fibroblast and nitrous oxide-treated HeLa cell models. The nucleus was the most 
sensitive cellular compartment to 5-methylTHF accumulation, with levels increasing 
greater than 4-fold. Vitamin B12 depletion decreased de novo dTMP biosynthesis 
capacity by 5-35%, whereas de novo purine synthesis, which occurs in the cytosol, 
was not affected. Phosphorylated histone H2AX (γH2AX), a marker of DNA double-
strand breaks (DSBs), was increased in vitamin B12 depletion, and this effect was 
exacerbated by folate depletion. These studies also revealed that 5-formylTHF, a 
slow, tight-binding inhibitor of SHMT, was enriched in nuclei, accounting for 35% of 
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folate cofactors, explaining previous observations that nuclear SHMT is not a robust 
source of one-carbons for de novo dTMP biosynthesis. These findings indicate that a 
nuclear 5-methylTHF trap occurs in vitamin B12 depletion, which suppresses de novo 
dTMP biosynthesis and causes DNA damage, accounting for the pathophysiology of 
megaloblastic anemia observed in vitamin B12 and folate deficiency.  
Keywords: folate | vitamin B12 | 5-methyltetrahydrofolate trap | thymidylate | γH2AX |  
Significance Statement: Vitamin B12 deficiency causes hematological and 
neurological pathologies by impairing DNA synthesis. The nucleus is shown to be 
highly sensitive to 5-methyltetrahydrofolate accumulation induced by vitamin B12 
depletion in the cytosol, leading to impaired nuclear de novo thymidylate synthesis 
and genome instability. These effects of the 5-methyltetrahydrofolate trap are 
exacerbated by folate depletion in nitrous oxide-treated HeLa cells and methionine 
synthase (MTR) loss-of-function fibroblasts. These results provide a mechanism 
underlying vitamin B12-folate interrelationships that underlie megaloblastic anemia 
and neural tube defects (NTDs).  
Introduction 
Vitamin B12 (cobalamin) deficiency disproportionately affects older adults and 
pregnant women (1). It can arise from inadequate dietary intake or impaired 
absorption, with the latter accounting for the majority of cases (2, 3). Vitamin B12 is 
essential for maintaining nervous system function as well as hematopoiesis, as the 
classic sequelae of deficiency include irreversible neurological damage and/or 
reversible hematological changes (2, 4). The clinical manifestations of vitamin B12 
deficiency have been known for decades, and it is known that high levels of folate 
intake can mask megaloblastic anemia (5), indicating that increased intracellular 
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folate levels can rescue some metabolic consequences of  vitamin B12 deficiency. 
Conversely, data from cross-sectional studies suggest that low vitamin B12 and 
elevated folate status exacerbate symptoms of cognition and anemia (6, 7) as well as 
biochemical indicators of vitamin B12 deficiency (7); however, there is no mechanistic 
understanding in support these observations. 
There are two enzymes that require vitamin B12 as a cofactor in mammals: 
methionine synthase (MTR), which functions in the cytosol, and L-methylmalonyl-
coenzyme A (coA) mutase (MUT), which functions in the mitochondria (4). MTR is 
both vitamin B12- and folate-dependent, and catalyzes the conversion of 
homocysteine to methionine in a two-step process. In the first step, the methyl group 
from 5-methylTHF is transferred to cobalamin, thereby creating methylcobalamin and 
releasing THF. In the second step, the methyl group from methylcobalamin is 
transferred to homocysteine for methionine synthesis (4). Consequences of reduced 
MTR activity include elevated homocysteine in tissue and plasma, a biomarker 
associated with adverse health outcomes including risk for neural tube defects 
(NTDs) (8), and impaired methylation status, as methionine is required for the 
synthesis of S-adenosylmethionine (AdoMet), the universal methyl donor required for 
over 100 cellular methylation reactions (9). Reduced MTR activity also leads to the 
trapping of cellular folate as 5-methyltetrahydrofolate (5-methylTHF), as the 
methylenetetrahydrofolate reductase (MTHFR)-catalyzed conversion of 5,10-
methyleneTHF to 5-methylTHF is irreversible in vivo (Fig. 3.1) (10). The “5-
methylTHF trap” is associated with the onset of megaloblastic anemia, which is 
characterized by an enlarged reticulocyte cytosol, immature nuclei, and incomplete 
DNA replication and cell division due to inadequate dTMP biosynthesis (Fig. 3.1) (2, 
5, 11). 
  56 
 
Figure 3.1. Folate- and vitamin B12-mediated one-carbon (1C) metabolism is 
compartmentalized within the cell. The hydroxymethyl group of serine is a primary 
source of 1C units, and can enter the pool of activated 1C units by SHMT-catalyzed 
cleavage of serine. Otherwise, serine and glycine are converted to formate in 
mitochondria, which traverses to the cytosol and nucleus where it is condensed with 
THF by MTHFD1. 1C metabolism in the cytosol includes the de novo synthesis of 
purines and the remethylation of homocysteine to methionine. Vitamin B12 is a 
required cofactor for MTR. De novo dTMP biosynthesis occurs in the nucleus, 
catalyzed by the enzymes SHMT1, SHMT2α, TYMS, and DHFR, which undergo 
SUMOylation leading to nuclear import in S-phase. 5,10-methyleneTHF is 
synthesized by SHMT or MTHFD1 for de novo dTMP synthesis. AdoHcy, S-
adenosylhomocysteine; AdoMet, S-adenosylmethionine; AICAR Tfase, 
aminoimidazolecarboxamide ribonucleotide transformylase; DHF, dihydrofolate; 
DHFR, dihydrofolate reductase; GAR Tfase, glycinamide ribonucleotide 
tranformylase; MTHFS, methenyltetrahydrofolate synthetase; MTHFR, 
methylenetetrahydrofolate reductase; MTR, methionine synthase; SHMT, serine 
hydroxymethyltransferase; SUMO, small ubiquitin-like modifier; THF, tetrahydrofolate; 
TYMS, thymidylate synthase. Figure adapted from Field et al. 2015 (47). 
 
 
Figure 1
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The proposed mechanisms underlying vitamin B12 deficiency-induced 
megaloblastic anemia are based on an assumption that both the homocysteine 
remethylation and de novo dTMP biosynthesis pathways function in the cytosol (12, 
13). However, there is increasing evidence that de novo dTMP biosynthesis occurs in 
the nucleus at sites of DNA synthesis (14). The enzymes that participate in de novo 
dTMP biosynthesis, serine hydroxymethyltransferase 1 and 2α (SHMT1, SHMT2α), 
dihydrofolate reductase (DHFR), methylenetetrahydrofolate dehydrogenase 1 
(MTHFD1), and thymidylate synthase (TYMS) undergo modification by the small 
ubiquitin-like modifier (SUMO) protein, and translocate to the nucleus where they 
form a complex at sites of DNA replication and repair (Fig. 3.1) during S-phase or in 
response to DNA damage (14–17). SHMT serves as an essential scaffold protein that 
connects this multienzyme complex to the nuclear lamina (14), but does not serve as 
a primary source of one-carbon units, as most one-carbons incorporated into dTMP 
are derived from formate via MTHFD1 (18). TYMS methylates deoxyuridylate (dUMP) 
using 5,10-methyleneTHF as the cofactor to produce dTMP and dihydrofolate (DHF). 
DHF is reduced to THF by DHFR, which is NADPH-dependent (Fig. 3.1). Insufficient 
concentrations of intracellular folate or impairments in nuclear localization of the de 
novo dTMP biosynthesis complex can lead to elevated uracil levels in DNA (19, 20). 
Low intracellular vitamin B12 concentrations and/or status can increase markers of 
genome instability including chromosomal abnormalities (21, 22), DNA strand breaks 
(23), and uracil content in DNA (24, 25). The mechanisms underlying the interactions 
between folate and vitamin B12 in maintaining genome stability and their contributions 
to human disease are unresolved. There is evidence that the cytosolic and nuclear 
folate cofactor pools are distinct. Unlike the cytosol, the nucleus is resistant to folate 
depletion when total cellular folates are depleted (26). Therefore, it is not clear if an 
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accumulation of 5-methylTHF in the cytosol during vitamin B12 depletion influences 
folate cofactor pools in the nucleus.  
We investigated the impact of vitamin B12 depletion on nuclear dTMP 
synthesis in two models of vitamin B12 deficiency: human fibroblasts with loss-of-
function mutations in MTR that comprise the inborn errors of cobalamin metabolism 
complementation group G (cblG) (27), and HeLa cells treated with nitrous oxide. The 
nucleus was observed to be highly sensitive to 5-methylTHF accumulation in vitamin 
B12 depletion, which led to depressed rates of de novo dTMP biosynthesis and 
increased genome instability. We also demonstrate that the nucleus is enriched in 5-
formylTHF cofactors, which are slow, tight-binding inhibitors of SHMT (28). This 
observation accounts for the lack of nuclear SHMT catalytic activity in de novo dTMP 
biosynthesis. These findings link vitamin B12 depletion to nuclear 5-methylTHF 
accumulation, impaired DNA synthesis, and genome instability, and provide a 
mechanism underpinning vitamin B12-associated pathologies. 
Results 
5-methylTHF is enriched in nuclei of vitamin B12-depleted HeLa cells and in 
cblG patient fibroblasts. Intracellular 5-methylTHF was 2.5-fold higher in cblG 
(WG4215) compared to control (MCH058) fibroblasts (p=0.01), with the elevation in 
5-methylTHF occurring at the expense of 10-formylTHF (p=0.009) and 5-formylTHF 
(p=0.03) (Fig. 3.2A). THF was not detected in either MTR-null or control fibroblasts. 
HeLa cells cultured in vitamin B12-depleted conditions exhibited a 1.75-fold increase 
in intracellular 5-methylTHF (p=0.0002), and a 50% decrease in THF (p=0.001) 
compared to HeLa cells maintained in vitamin B12-replete media (Fig. 3.2B). Nuclei 
isolated from vitamin B12-depleted HeLa cells exhibited a more than 4-fold enrichment 
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of 5-methylTHF (p=0.002), whereas THF levels decreased by greater than 50% 
(p=0.02) (Fig. 3.2C) compared to vitamin B12-replete HeLa cells. Nuclear 10-
formylTHF pools were 7.5-fold lower in nuclei isolated from HeLa cells maintained in 
vitamin B12-depleted conditions compared to vitamin B12-replete cells (p=0.02). 
Interestingly, 5-formylTHF was enriched in nuclei compared to total cellular 5-
formylTHF levels in HeLa cells (p=0.002) (Fig. 3.2B,C).  
 
Figure 3.2. Vitamin B12 depletion or MTR disruption results in elevated 5-methylTHF 
in cells (A,B) and nuclei (C). (A) Distribution of folate one-carbon forms in human 
fibroblasts. The percentages of folate forms are shown for one cell line of each cblG 
(WG4215, white bars) and control (MCH058, gray bars). (B,C) Nitrous oxide-induced 
changes in folate one-carbon distribution in HeLa cells (B) and nuclei (C). The 
percentages of folate forms present in HeLa cells and nuclei maintained in vitamin 
B12-depleted (white bars) or replete (gray bars) conditions are shown. All 
measurements were made in duplicate. Data are shown as mean ± standard 
deviation (S.D.). Differences in folate forms between replete and depleted conditions 
were determined by a Student’s 2-tailed t-test. For (C), a Western blot confirmed that 
nuclei were free of cytoplasmic contamination (Fig. S3.5). In A-C, statistical 
significance is denoted as follows: NS = Not significant (p > 0.05); * = 0.01 < p < 0.05; 
** = 0.01 < p < 0.001; *** = p < 0.001. 
 
 
Folate and vitamin B12 depletion interact to increase DNA damage in HeLa cells. 
Both folate depletion and vitamin B12 depletion independently increased γH2AX 
immunostaining (Fig. 3.3, 2B-E and 3B-E). Intracellular folate concentrations were 8-
fold lower in cells cultured in folate-depleted media (5 nM) compared to cells cultured 
in folate-replete (25 nM) media at the time of γH2AX staining and quantification 
(p<0.0001) (Fig. S3.6). Vitamin B12 depletion significantly increased the percentage of 
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cells with high γH2AX immunostaining, a marker of DNA DSBs, in all phases of the 
cell cycle compared to vitamin B12- and folate-replete conditions (Fig. 3.3, 1B-E vs. 
3B-E). This effect was exacerbated by folate deficiency (Fig. 3.3, 1B-E vs. 4B-E). 
Importantly, the difference in the percentage of cells with high γH2AX immunostaining 
between vitamin B12-depleted conditions was statistically significant (Fig. 3.3, 3B-E 
vs. 4B-E) (Table S3.1, 5B-E). Within treatment conditions, the greatest increase in the 
percentage of cells with high γH2AX immunostaining was observed during G2/M (Fig. 
3.3, 1-4E).  
Folate depletion, but not MTR loss-of-function, increases DNA damage in 
human fibroblasts. In fibroblasts, folate depletion significantly increased γH2AX 
immunostaining, as quantified by the percentage of nuclear area with γH2AX 
(p<0.0001) (Fig. 3.4A). MTR loss-of-function did not significantly affect γH2AX levels 
when comparing cblG (WG4215 & WG4460) and control fibroblast lines (MCH058 & 
MCH064) cultured under either folate-replete or depleted culture conditions (p>0.05) 
(Fig. 3.4A). 
Vitamin B12 and folate depletion impair de novo dTMP biosynthesis. In HeLa 
cells, vitamin B12 depletion impaired de novo dTMP synthesis by 5% compared to 
vitamin B12-replete cells (p=0.02) (Fig. 3.4B). A combined folate and vitamin B12 
depletion decreased de novo dTMP capacity by 35% (p<0.0001). In cblG fibroblasts, 
MTR loss-of-function decreased the relative rate of de novo dTMP synthesis by 
approximately 25% (p<0.0001) (Fig. 3.4C).    
  61 
 
 
Figure 3.3. Vitamin B12 depletion induces changes in γH2AX, a marker of DNA 
damage in HeLa cells. Cells were stained for DNA content (Vybrant Violet; 1-4A) and 
γH2AX (FITC; 1-4 B-E); individual plots depict the cell count (Y-axis) versus 
fluorescence intensity (X-axis). The high γH2AX parameter is a threshold defined by 
the mean top 2.5% of cells in G1, S, and G2/M (‘all cells’) stained for γH2AX in the 
vitamin B12- and folate-replete condition (1B), and this gate was uniformly applied to 
all conditions and cell cycle phases. Each plot shows the mean percent high γH2AX ± 
S.D. for triplicate measurements for each experimental condition and cell cycle 
phase. Individual triplicate measurements for each condition are plotted relative to the 
corresponding mean γH2AX values in the vitamin B12- and folate-replete condition 
(hatched histograms, 1B-E). The grey, pink, yellow, and green colors correspond to 
the γH2AX fluorescence intensity for all cells, G1, S, and G2/M cell cycle phases, 
respectively. Asterisks designate statistical significance in percent high γH2AX values 
between treatment conditions and cell cycle phases compared to the corresponding 
phases in the vitamin B12- and folate-replete condition (Table S3.1). The greatest 
percentage of cells with high γH2AX within conditions was observed in G2/M under 
vitamin B12- and folate-depleted conditions (p<0.001; 4E). The vitamin B12-depleted 
and folate-replete condition in row 3 contains duplicate measurements. The 
experiment was performed twice (see Fig. S3.7). Folate-replete, 25 nM (6S) 5-
formylTHF in culture media; Folate-depleted, 5 nM (6S) 5-formylTHF in culture media. 
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The statistical significance is represented as follows: NS = Not significant (p > 0.05); * 
= 0.01 < p < 0.05; ** = 0.01 < p < 0.001; *** = p < 0.001. 
 
 
Figure 3.4. Metabolic effects of vitamin B12 depletion are exacerbated by folate 
depletion. (A) Folate depletion (gray bars) significantly increases the formation of 
γH2AX in MTR-null and control fibroblasts compared to those maintained in folate-
replete conditions (white bars). Data are shown as mean percent thresholded area ± 
S.E. The number of cells analyzed per fibroblast line and treatment was: MCH064 25 
nM folate: 648; MCH064 5nM folate: 542; MCH058 25 nM folate: 623; MCH058 5 nM 
folate: 773; WG4460 25 nM: 884; WG4460 5 nM folate: 851; WG4215 25 nM folate: 
645; WG4215 5 nM folate: 625. Folate exposure predicted γH2AX response 
(p<0.0001) in three of the four cell lines, but MTR loss-of-function did not (p>0.05), as 
determined by a linear mixed-effects model. (B) Rates of de novo dTMP biosynthesis 
relative to salvage pathway synthesis in HeLa cells maintained in vitamin B12- and 
folate-replete or depleted conditions. Vitamin B12 depletion and folate-replete 
conditions impaired de novo dTMP synthesis capacity by 5% compared to vitamin 
B12- and folate-replete conditions (p=0.02). A combined vitamin B12 and folate 
depletion decreased rates of de novo dTMP synthesis by 35% (p<0.0001). Data are 
shown as mean ± S.D. (C) Rates of de novo dTMP biosynthesis relative to salvage 
pathway synthesis in cblG (WG4215 & WG4460) and control (MCH058 & MCH064) 
human fibroblasts maintained in vitamin B12-replete or depleted media without folate. 
cblG fibroblasts exhibited a 25% reduction in de novo dTMP capacity compared to 
control fibroblasts (p<0.0001). Data are shown as means ± S.E. (n=12 per group). 
HF, 25 nM (6S) 5-formylTHF in culture media; LF, 5 nM (6S) 5-formylTHF in culture 
media; N2O, nitrous oxide. 
 
 
MTR loss-of-function and folate depletion do not impair de novo purine 
biosynthesis. Intracellular folate depletion did not significantly impair de novo purine 
biosynthesis in human fibroblasts (p>0.05). One control and two cblG cell lines 
exhibited similar rates of de novo purine biosynthesis, as determined by the ratio of 
14C-formate/3H-hypoxanthine incorporation into nuclear DNA (Fig. S3.8).  One control 
cell line showed reduced de novo purine biosynthesis. 
0 
5 
10 
15 
20 
25 
30 
MCH064 MCH058 WG4460 WG4215 
γH
2A
X 
Th
re
sh
ol
d 
A
re
a 
%
 
A. B. C. 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
0.35 
+B12+HF-N2O -B12+HF+N2O -B12+LF+N2O 
M
ea
n 
14
C
-d
U
/3 H
-th
y 
 
p=0.02 
p<0.0001 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
0.35 
0.4 
MCH064 & 
MCH058 
WG4215 & 
WG4460 
M
ea
n 
14
C
-d
U
/3 H
-th
y 
 
p<0.0001 
  63 
Vitamin B12 depletion and intracellular folate concentrations influence the 
source of one-carbon units for dTMP biosynthesis. The incorporation of one-
carbons derived from L-[2,3,3-2H3]-serine into the de novo dTMP biosynthesis 
pathway either as formate (CD1 via MTHFD1) or the hydroxymethyl group of serine 
(CD2 via SHMT), as indicated by the ratio of CD1/(CD1+CD2) was increased by 12% 
in HeLa cells grown under vitamin B12-depleted and folate-replete conditions 
compared to HeLa cells cultured in vitamin B12- and folate-replete media (p=0.007) 
(Fig. S3.9A). The difference between vitamin B12 depleted conditions was significant 
(p=0.002) (Fig. S3.9A). These findings indicate that vitamin B12 depletion and folate-
replete conditions decrease the contribution of SHMT-derived single carbons (CD2) 
compared to folate- and vitamin B12-depleted conditions. There was no difference in 
the CD1/(CD1+CD2) ratio between cblG (WG4215 & WG4460) and control (058MCH 
& MCH064) fibroblasts cultured in folate-replete conditions (Fig. S3.9B). 
Discussion 
Previous studies have described the impact of the vitamin B12 deficiency-
induced “5-methylTHF trap” in terms of limiting available cytosolic THF cofactors for 
dTMP synthesis (5, 11). Our work was motivated by recent findings that the de novo 
dTMP biosynthesis pathway is present in the nucleus during S-phase of the cell cycle 
and forms a complex at sites of DNA replication and repair (14, 16, 29). SHMT serves 
as an essential scaffold for the assembly of this complex but makes only minor 
contributions as a source of one-carbon units for dTMP synthesis (14, 18). Proper 
assembly of the metabolic complex and adequate levels of unsubstituted THF 
cofactors in the nucleus are required to maintain adequate dTMP synthesis and 
genome integrity (19, 20). Mice with reduced Shmt1 expression exhibit 2.5- to 4.5-fold 
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elevations in levels of uracil in nuclear DNA (22), and elevated levels of uracil 
incorporation into DNA result in loss of DNA integrity (20). 
This study demonstrates that vitamin B12 depletion in HeLa cells traps nuclear 
folate as 5-methylTHF, impairs rates of de novo dTMP biosynthesis, and leads to 
genome instability. These effects of vitamin B12 depletion were exacerbated by folate 
depletion. In vitamin B12-depleted HeLa cells, the elevations in 5-methylTHF were 
more pronounced in nuclei compared to whole cells, with a greater than 4-fold 
increase in nuclear 5-methylTHF (Fig. 3.2B,C). The sensitivity of the nucleus to 5-
methylTHF accumulation is striking, given that 5-methylTHF is synthesized in the 
cytosol. CblG fibroblasts, which lack MTR activity, exhibit elevated levels of 5-
methylTHF compared to control fibroblasts, and therefore serve as a model of severe 
vitamin B12 depletion (Fig. 3.2A). Loss of MTR activity seen in cblG fibroblasts was 
also associated with reduced de novo dTMP biosynthesis capacity compared with 
control fibroblasts (Fig. 3.4C).  In contrast to HeLa cells, the reduction in de novo 
dTMP biosynthesis did not result in elevations in γH2AX immunostaining (Fig. 3.4A) 
in MTR loss-of-function fibroblasts. These observations may account for differences 
in the clinical manifestation of vitamin B12 deficiency in that specific cell types, 
including neural tissue and bone marrow, exhibit increased sensitivity to vitamin B12 
deficiency (2).   
The effect of impaired de novo dTMP biosynthesis on increasing genome 
instability as evidenced by increased γH2AX immunostaining could result from two 
potential mechanisms. γH2AX levels may increase as a result of reduced replication 
fork movement (31), or due to base excision repair pathways that remove uracil from 
DNA (32). Reduced replication fork movement has been reported in lymphocytes 
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from patients with megaloblastic anemia (33). When stratified by cell cycle, the 
γH2AX immunostaining observed as a result of vitamin B12- and folate depletion 
occurred primarily during S-phase and G2/M phase of the cell cycle (Fig. 3.3). The 
presence of a stalled replication fork may be responsible for the increased γH2AX 
immunostaining that is observed during S-phase, as vitamin B12 depletion decreases 
the amount of nuclear THF available for subsequent nucleotide biosynthesis (Fig. 
3.2C & 4B,C). Alternatively, it is possible that the DSBs observed in S- and G2/M 
phases of the cell cycle may arise as a result of base-excision repair of genomic 
uracil in DNA (32). In HeLa cells, folate depletion exacerbated genome instability 
associated with vitamin B12 depletion, with high rates of genome instability observed 
in all phases of the cell cycle including G1 phase (Fig. 3.3, 4B-E). Our findings are in 
contrast to observational studies reporting that high folate status worsens clinical 
symptoms (6, 7) and biochemical indicators of vitamin B12 deficiency (7).   
This study provides a new role for 5-formylTHF in de novo dTMP synthesis, as 
it revealed that nuclear folate pools are enriched in 5-formylTHF. The role of 5-
formylTHF in mammalian one-carbon metabolism has been elusive. It does not serve 
as a metabolic cofactor, but rather has been proposed to serve as a stable, storage 
form of folate, and is an inhibitor of folate-dependent enzymes including SHMT (34). 
SHMT and MTHFS participate in a futile cycle that regulates cellular 5-formylTHF 
levels. SHMT synthesizes 5-formyTHF, whereas MTHFS converts 5-formylTHF back 
to a metabolically active cofactor (Fig. 3.1) (35). 5-formylTHF is a minor component of 
the total cellular folate pool (8%), but accounts for 35% in nuclei.  The enrichment of 
5-formylTHF in HeLa nuclei provides a mechanism for previous observations that the 
majority of one-carbon units incorporated into dTMP are derived from formate via 
MTHFD1 and not from serine via SHMT1 and/or SHMT2α (Fig. 3.1) (15, 18). The 5-
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formylTHF present in the nucleus is expected to inhibit SHMT1 and SHMT2α, as 5-
formylTHF is a slow, tight-binding inhibitor of SHMT (28). The increase in 
incorporation of one-carbons from MTHFD1 into dTMP in folate-replete and vitamin 
B12-deficient HeLa cells is likely explained by the increased pool of 5-methylTHF, 
which also binds and inhibits SHMT (Fig. S3.9A) (28). It is unclear if nuclear SHMT 
activity and, hence, de novo dTMP biosynthesis is regulated by changes in nuclear 5-
formylTHF levels. 
This study provides a mechanism whereby vitamin B12 depletion in the cytosol 
impairs de novo dTMP synthesis in the nucleus by trapping folate as 5-methylTHF, 
and this discovery can be extended to other vitamin B12-associated human 
pathologies. Megaloblastic anemia is characterized by impaired maturation and 
proliferation of red blood cell precursors during hematopoiesis that results in an 
accumulation of cells in S-phase, as the G2 to M transition cannot be completed for 
cell division because of inadequate THF pools (2). Furthermore, maternal vitamin B12 
deficiency has been associated with NTDs (36–38). NTDs arise when the neural folds 
fail to fuse entirely during neurulation in early embryogenesis, a period of rapid 
growth that places demands on nucleotide pools for the cell division required to 
complete neural tube closure. Folic acid supplementation reduces the occurrence and 
recurrence of NTDs by up to 70% (39, 40). Impairments in de novo dTMP synthesis, 
have been implicated in the etiology of folate-responsive NTDs, both in human 
studies and in animal models (41–43). The role of a nuclear 5-methylTHF trap 
resulting from vitamin B12 depletion in neural tube closure warrants further 
investigation. 
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Contributions: AMP performed all experiments in Chapter 3. EK provided technical 
advice and expertise, helpful discussions, and contributed to the data analysis in the 
experiments in Fig. 3.3 & 3.4A. 
Experimental Procedures 
Cell Culture. Two patient [WG4215 & WG4460 cblG (MTR loss-of-function)] and two 
Montreal Children’s Hospital (MCH) control fibroblast cell lines (MCH058 and 
MCH064) were maintained in MEM, α-modification (α-MEM; HyClone) supplemented 
with 10% (vol/vol) fetal bovine serum (FBS, Hyclone) and 1X Pen-Strep (Mediatech). 
For all studies, cells were maintained in custom defined media (Hyclone, 
#SH3A4302.01) with 10% (vol/vol) dialyzed FBS (Hyclone). Culture medium 
contained 2 mM glycine (MP Biomedicals), 1 mg/L pyridoxine (Sigma), 250 µM 
methionine (Sigma), 1.35 µM cyanocobalamin (vitamin B12-replete, Sigma), and either 
5 nM (6S) 5-formylTHF (folate-deplete) or 25 nM (6S) 5-formylTHF (folate-replete) 
(Schircks Laboratories). 
Nitrous Oxide (N2O)-induced Inactivation of Methionine Synthase (MTR). To 
inactivate MTR activity, HeLa cells were placed in a hypoxia incubator chamber 
(Stemcell Technologies), and treated with a nitrous oxide (N2O) gas mixture 
consisting of 50% N2O, 45% balance air, and 5% CO2 (Airgas). At time zero, the N2O 
gas mixture was delivered to the chamber at 20 psi for 5 min according to 
manufacturer’s instructions, and this step was repeated 1 h later; the chamber was 
flushed with the N2O gas mixture for 5 min twice every 24 h. Prior to initiating 
treatment with N2O, culture medium on appropriate plates was replaced with culture 
medium purged with N2O for 5 min, and fresh media was administered to plates that 
did not undergo N2O treatment. 
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Determination of Folate Cofactor One-carbon Distribution. HeLa cells (4.5x105) 
were seeded in 10-cm tissue culture plates (Corning), cultured in folate-free modified 
culture medium with or without cyanocobalamin, and cultured to 60-80% confluency. 
Plates were rinsed twice with 1X PBS (Cellgro) and replaced with 3 mL of medium 
containing 50 nM [3H]-folinic acid (Moravek Biochemicals). Following a 24 h 
incubation, 7 mL of vitamin B12-replete or depleted medium purged with N2O gas was 
added to the appropriate plates, which were cultured for 24 hours in the hypoxia 
chamber. Cell monolayers were washed, harvested, and intracellular folates were 
extracted as previously described (44). Fibroblasts were cultured with labeled folates 
as described elsewhere (44). Folate one-carbon forms were separated and quantified 
using reverse phase HPLC as previously described (45).  
Determination of Nuclear Folate Cofactor One-carbon Distribution. HeLa cells 
(4x105) were plated as described above. Following 48 h in culture, plates were 
labeled with 50 nM [3H]-folinic acid (Moravek Biochemicals) for 24 h, and then 
maintained as previously described for another 48 h. Nuclei were extracted using the 
REAP method (46). The nuclear pellet was resuspended in 200 µL folate extraction 
buffer (44) and sonicated twice using a Branson Sonifier 150 on level V3 for 5 
seconds on ice. Folate one-carbon forms were separated and quantified using 
reverse phase HPLC as previously described (45).   
Immunoblotting. Proteins (20 µg per lane) were separated on a 4-20% (vol/vol) 
SDS-PAGE gel (Novex), and transferred onto Immobilon-P PVDF membranes 
(Millipore). Membranes were blocked overnight in 5% (wt/vol) bovine serum albumin 
(BSA; Sigma) in PBS with 0.2% Tween-20 (Amresco) and 0.02% sodium azide 
(Sigma). Full-length α-tubulin protein (52 kD) was detected using mouse anti-human 
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monoclonal primary antibody (mAb) at 1:1000 dilution (Active Motif), and a 1:10,000 
dilution of HRP conjugated goat-anti mouse secondary antibody (Pierce). Full-length 
Lamin B1 protein (68 kD) was detected using a rabbit anti-human monoclonal 
antibody (Cell Signaling) at 1:1000 dilution, and a 1:5,000 dilution of HRP-conjugated 
donkey anti-rabbit secondary (Pierce). Secondary antibodies were incubated in 10% 
(wt/vol) nonfat dry milk in PBS and 0.1% NP-40 (US Biologicals). The membranes 
were incubated in SuperSignal West Pico Chemiluminescent Substrate (Pierce), and 
exposed to autoradiography.  
dU Suppression Assay. The contributions of the de novo and salvage pathways to 
dTMP biosynthesis were measured in cells by exposure to [14C]-deoxyuridine and 
[3H]-thymidine, as described elsewhere (47). Briefly, fibroblasts (2x104 cells/well) 
were plated in triplicate in 6-well plates (Corning) and allowed to undergo two 
doublings in vitamin B12-replete or depleted modified media lacking folate and 
containing 500 nM [3H]-thymidine (Perkin-Elmer) and 10 µM [14C]-deoxyuridine 
(Moravek). HeLa cells were plated in modified media containing vitamin B12 and/or 
folate for 24 h. The appropriate treatment groups were exposed to nitrous oxide gas 
for 48 h, which represented two cell doublings. Cells were re-plated in triplicate (2x105 
cells/well) in 6-well plates containing [14C]-dU and [3H] thymidine. Cells in N2O 
treatment groups were returned to the chamber and exposed to N2O gas mixture for 
an additional 48 h. Cells were harvested and genomic DNA extracted with a DNA 
Isolation Kit for Cells and Tissues (Roche). The radioisotope quantification was 
performed as described previously (47). Statistical analyses were performed on HeLa 
cell data using a Student’s two-tailed t-test. Significance in fibroblasts was assessed 
using two-way ANOVA in JMP Pro 12 Software (SAS Corporation). Independent 
variables were fibroblast genotype, vitamin B12 (replete or deplete), and the 
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interaction term; the dependent variable was the ratio of 14C-dU to 3H-thymidine in 
nuclear DNA. 
Quantification of γH2AX by Flow Cytometry. The impact of vitamin B12 and/or 
folate depletion on γH2AX formation in HeLa cells was assessed using flow cytometry 
(48). Briefly, cells (1 x 106) were seeded in 10 cm plates in modified media 
supplemented with folate and/or cyanocobalamin. Vitamin B12 depletion was induced 
with the N2O gas mixture at 24 h post-plating and held for 48 h. Cells were re-seeded 
at a 1:5 density in triplicate, and treated with N2O gas mixture for an additional 48 h. 
One aliquot of cells per treatment group was saved at harvest for the microbiological 
assay to quantify intracellular folate. For the positive control: 100 µM etoposide 
(Sigma) was added to culture medium in the positive control plate for 1 h prior to 
trypsinizing cells. For preparation of all samples: Cells were washed twice with 1X 
PBS and harvested with 1X Trypsin-EDTA for no longer than 5 min. Cells were 
pelleted at 3,700 rpm for 4 min at room temperature. Cell pellets were washed once 
with PBS prior to a final centrifugation. The supernatant was discarded, and pellets 
were incubated on ice until staining. For γH2AX staining: 150 µL of master mix 
containing Block-9 buffer, FITC-conjugated α-γH2AX antibody (1:3000; Millipore), and 
Vybrant Violet DNA stain (1:1000; Life Sciences) was added to each sample. Cell 
pellets were gently resuspended by vortexing and incubated on ice in the dark for 3 h. 
Samples were resuspended 1XPBS and strained immediately before each analysis. 
The samples were analyzed on a BD FACSAria flow cytometer using 488 and 405 
nm lasers for excitation of FITC and Vybrant Violet Dye Cycle Stain, respectively. 
Data was recorded for approximately 200,000 events per replicate, and initial gating 
excluded any debris and clumped cells. This population was further gated to exclude 
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those cells with a large area and width to obtain the parent gated population for 
γH2AX analyses.  
Quantification of high γH2AX. All post-run analyses for flow cytometry data files 
were performed in FCS Express 5 (De Novo Software). The parent population of cells 
stained for both DNA content (Vybrant Violet) and γH2AX (FITC) was gated for cell 
cycle (G1, S, and G2/M). The gate for ‘all cells’ comprised the G1, S, and G2/M 
phases analyzed together. Two gates for γH2AX included total γH2AX and high 
γH2AX. Total γH2AX refers to absolute FITC intensity. The gate for high γH2AX was 
determined by applying a threshold cutoff at the mean top 2.5% of cells across 
triplicates in the vitamin B12- and folate-replete (control) condition stained for total 
γH2AX (Fig. 3.3, 1B). This gate for high γH2AX was applied to replicates in all 
treatment conditions and cell cycle phases. Significance between the control and 
other treatment conditions in ‘all cells’, G1, S, and G2/M was assessed using a 2-way 
ANOVA. In this model, the independent variables included folate, vitamin B12, and the 
interaction term (folate x vitamin B12); the dependent variable was the percent high 
γH2AX for individual triplicates in each treatment and cell cycle. The percent high 
γH2AX values for triplicates were log-transformed to better satisfy the assumptions of 
the model. Specific pair-wise post-hoc comparisons were made between the percent 
high γH2AX in the control condition for all cells, G1, S, or G2/M to that observed in the 
corresponding cell cycle phase for each treatment column. A Bonferroni correction 
was applied to account for the multiple comparisons between conditions (n=4).  
Microbiological L. casei Assay. The concentration of total folate in HeLa cells was 
determined using the microbiological L. casei assay as described elsewhere (49).  
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Formate Suppression Assay. Flux through the de novo and salvage purine 
biosynthetic pathways was measured in human fibroblasts by quantifying the amount 
of 14C-formate (de novo) and 3H-hypoxanthine (salvage) incorporated into nuclear 
DNA as previously described (47). Cells (2x104) were seeded in triplicate in 6-well 
plates in folate-replete or folate-depleted culture medium with cyanocobalamin and 
containing 20 µM [14C]-formate (Moravek) and 200 nM [3H]-hypoxanthine (Moravek).  
Cells were cultured for 2 doublings. Cell pellets, DNA extraction, and radioisotope 
abundance in DNA were performed as described elsewhere (see dU Suppression 
Assay). Statistical analyses were performed using a two-way ANOVA to assess the 
impact of folate, fibroblast genotype, as well as the interaction term on the mean ratio 
of 14C-formate/3H-hypoxanthine. The mean 14C/3H values were rank transformed to 
improve the normal distribution assumption of the model. 
γH2AX Immunostaining and Quantification. Cells (2x104) were seeded in duplicate 
on #1.5 microscope cover glass slides (Fisher Scientific) in 6-well plates, and 
maintained in modified folate-replete or deplete culture medium with cyanocobalamin 
until approximately 80% confluent. Cell fixation and immunostaining was performed 
as previously described (47) with the modification that 0.5% Triton in PBS was added 
for permeabilizing cells and diluting the primary antibody. Representative images 
(n=10 per slide) were recorded with a Leica TCS SP2 confocal microscope. 
Quantification of the percent γH2AX positive area for each cell was performed as 
previously described (47). The percent thresholded area of γH2AX staining for each 
cell within an image were averaged to improve the normal distribution assumption, 
and statistical analyses were performed using the averaged values across all 
treatments (n=160). A linear mixed-effects model assessed the impact of folate and 
vitamin B12 status on γH2AX response (mean % threshold area). Fixed effects 
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included: folate, vitamin B12, and the interaction term. Random effects included: 
subject and slide. Slide was nested within subject.  
Stable Isotope Tracer Studies. The flux of isotopically labeled one-carbon units into 
the de novo dTMP biosynthesis pathway was quantified in thymidine in DNA using L-
[2,3,3-2H3]-serine as described previously (18). Briefly, human fibroblasts (8 x 105) 
were plated in duplicate in folate-replete modified culture medium containing 
cyanocobalamin (See Cell Culture) supplemented with 250 µM L-[2,3,3-2H3]-serine 
(Cambridge Isotope Laboratories) and allowed to undergo 2 doublings. HeLa cells 
(4x105) were plated in duplicate for three media conditions: 1) vitamin B12- and folate-
replete, 2) vitamin B12-deplete and folate-replete, and 3) vitamin B12- and folate-
deplete. Vitamin B12 depleted conditions were treated with nitrous oxide for 48 h 
following 24 h in culture. All groups were then seeded at a 1:4 density in duplicate 
into appropriate media containing 250 µM L-[2,3,3-2H3]-serine, treated with nitrous 
oxide for an additional 48 h to allow for 2 population doublings. The cell pellets were 
washed twice with PBS, and genomic DNA was isolated as previously described (see 
dU Suppression Assay).  
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Supplemental Information 
 
Figure S3.5. Western blot of whole cell, cytosolic, and nuclear fractions for nuclear 
(lamin B1) and cytosolic (α-tubulin) marker proteins from HeLa cells harvested in 
tandem with those cells used for quantifying nuclear one-carbon folate forms (refer to 
Fig. 3.2C). The absence of α-tubulin in the lanes corresponding to nuclear fractions 
confirms the lack of cytosolic contamination in nuclei. Lane designations: WCE, whole 
cell extract; cyto, cytosolic; nuc, nuclear. N2O, nitrous oxide. 
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Figure S3.6. Intracellular folate concentrations in HeLa cells assayed for γH2AX at 
the time of staining and quantification (refer to Fig. 3.3). The intracellular folate 
concentrations were 8-fold higher in HeLa cells maintained in folate-replete (25 nM) 
media compared to those cultured in folate-depleted (5 nM) conditions (p<0.0001). 
Data are shown as the mean ± S.D. of n=4 groups for each folate replete or folate 
depleted condition. Significance was determined by using a Student’s two-tailed t-
test. 
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Figure S3.7. Vitamin B12 depletion induces changes in γH2AX, a marker of DNA 
damage, in the S and G2/M phases of the cell cycle in HeLa cells. Cells were stained 
for DNA content (Vybrant Violet; 1-3A) and γH2AX (FITC; 1-3 B-E); individual plots 
depict the cell count (Y-axis) versus fluorescence intensity (X-axis). The high γH2AX 
parameter is a threshold defined by the mean top 2.5% of cells in the G1, S, and 
G2/M (‘all cells’) stained for γH2AX in the vitamin B12- and folate-replete condition 
(1B), and this gate was uniformly applied to all conditions and cell cycle phases. Each 
plot shows the mean percent high γH2AX ± S.D. for triplicates for each experimental 
condition and cell cycle phase. Individual triplicates stained for γH2AX in each 
condition are plotted relative to the corresponding mean γH2AX values in the vitamin 
B12- and folate-replete condition (hatched histograms, 1B-E). Asterisks designate 
statistical significance in percent high γH2AX values between treatment conditions 
and cell cycle phase compared to the corresponding phases in the vitamin B12- and 
folate-replete condition (1B-E). The grey, pink, yellow, and green colors correspond to 
the γH2AX fluorescence intensity for all cells, G1, S, and G2/M cell cycle phases, 
respectively. The greatest percentage of cells in high γH2AX within conditions was 
observed in G2/M under vitamin B12- and folate-depleted conditions (p<0.001; 3E). A 
combined vitamin B12 and folate depletion exacerbated the percent high γH2AX 
observed in HeLa cells compared to cells maintained in vitamin B12-depleted and 
folate-replete culture conditions in all cells, S, and G2/M (compare 2A,D-E to 3A,D-E), 
and this difference in high γH2AX between conditions was significant for S phase 
(p=0.01) and G2/M (p=0.0003). Statistical significance was determined using a one-
way ANOVA. The dependent variable was log-transformed percent high γH2AX, and 
the independent variable was vitamin B12 and folate level. Folate-replete, 25 nM (6S) 
5-formylTHF in culture media; Folate-depleted, 5 nM (6S) 5-formylTHF in culture 
media. The statistical significance is represented as follows: NS = Not significant (p > 
0.05); * = 0.01 < p < 0.05; ** = 0.01 < p < 0.001; *** = p < 0.001. 
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Figure S3.8. Mean ratio of 14C-formate/3H-hypoxanthine incorporation into nuclear 
DNA in cblG (WG4215 and WG4460) and control (MCH064 and MCH058) fibroblasts. 
Data are shown as mean ± S.D. for fibroblast line and treatment. A two-way ANOVA 
revealed a non-significant effect of folate exposure (p>0.05) and a significant effect of 
fibroblast genotype (p=0.02) on the rank-transformed mean ratios of 14C/3H 
incorporated into nuclear DNA. HF, 25 nM (6S) 5-formylTHF; LF, 5 nM (6S) 5-
formylTHF. 
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Figure S3.9. Mean ratio of isotopically labeled one-carbon units from MTHFD1 (CD1) 
to the total number of labeled one-carbons containing 1 or 2 deuterium atoms 
generated from MTHFD1 (CD1) or SHMT (CD2), respectively, into thymidine in 
nuclear DNA in (A) HeLa cells and (B) human fibroblasts. (A) Vitamin B12-depleted 
and folate-replete conditions increased the contribution of labeled one-carbon units 
from MTHFD1 relative to SHMT by 12% compared to vitamin B12 and folate-replete 
conditions in HeLa cells (p=0.007). The ratios between vitamin B12-depleted 
conditions were significant (p=0.002). (B) In human cblG (WG4215 and WG4460) and 
control fibroblasts (MCH058 and MCH064) grown under high folate conditions, there 
was no difference in the contributions of one-carbon units from MTHFD1 (p>0.05). 
For (A) and (B), cells were plated in duplicate, and the data are shown as mean ± 
S.D. Statistical significance between conditions was assessed using a one-way 
ANOVA. The dependent variable was the log-transformed ratio of mean 
CD1/(CD1+CD2) and the independent variable was folate and vitamin B12 exposure. 
HF, 25 nM (6S) 5-formylTHF; LF, 5 nM (6S) 5-formylTHF. 
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Table S3.1. Fold differences in percent high γH
2A
X
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een control and experim
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2 w
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SUMMARY 
 
The overarching purpose of this work was to test for a metabolic link between 
cytosolic vitamin B12 deficiency and nuclear one-carbon metabolism, a goal motivated 
by the recent findings demonstrating compartmentalization between the folate-
dependent de novo dTMP biosynthesis and homocysteine remethylation pathways. 
These findings called into question those previous studies that have characterized the 
impact of the 5-methylTHF trap that occurs in vitamin B12-associated pathologies, 
including megaloblastic anemia, as depleting cytosolic folate cofactors for dTMP 
synthesis. This work additionally aimed to explore the vitamin B12-folate 
interrelationship in de novo dTMP biosynthesis, given the conflicting evidence with 
respect to elevated folate intakes in vitamin B12 deficiency and related worsening or 
improvement of clinical outcomes. These gaps in the literature called for a systematic 
investigation of these relationships with respect to genome stability and disease 
pathogenesis. A conceptual figure summarizing the findings from this work is included 
at the end of this section. 
The first aim of this work investigated the impact of maternal vitamin B12 
deficiency on NTD pathogenesis in embryos with impairments in de novo dTMP 
biosynthesis under conditions of folate-repletion and deficiency. Maternal vitamin B12 
deficiency caused vitamin B12-responsive NTDs in Shmt1-/- and Shmt1-/+ embryos but 
did not impair homocysteine remethylation or embryonic growth. Supplemental folate 
did not rescue rates of NTDs in vitamin B12 deficiency, suggesting that the 
neuroepithelium may not be rescued with folate in vitamin B12 deficiency, similar to 
what has been observed in the case of vitamin B12-associated neuropathies. The non-
significant rates of NTDs between the vitamin B12-deficient groups suggest that 
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elevated folate intakes do not exacerbate NTD incidence. Taken together, these 
findings indicate that neural tube closure is more sensitive than cytosolic 
homocysteine remethylation or embryonic growth. 
The second aim of this work sought to determine a mechanism by which 
cytosollc vitamin B12 depletion impairs nuclear de novo dTMP biosynthesis. We 
investigated this aim in two cell models of vitamin B12 deficiency, namely, MTR loss-
of-function human fibroblasts and nitrous oxide-treated HeLa cells. Both cell types 
exhibited increased intracellular 5-methylTHF compared to vitamin B12-replete HeLa 
cells or control fibroblasts. In contrast, the nucleus exhibited a marked increase in 5-
methylTHF accumulation compared to total cellular 5-methylTHF concentrations in 
vitamin B12-depleted HeLa cells, indicating that this compartment is the most sensitive 
to 5-methylTHF accumulation. Technical challenges prevented the quantification of 
nuclear one-carbon forms in human fibroblast lines.  
Vitamin B12 depletion depressed rates of de novo dTMP biosynthesis in both 
cell types. In vitamin B12-depleted HeLa cells, rates of de novo dTMP biosynthesis 
were further exacerbated by folate depletion. Vitamin B12 depletion in HeLa cells 
increased DNA damage under folate-replete conditions as quantified by 
phosphorylated histone H2AX (γH2AX), and this damage was exacerbated by folate 
depletion. When stratified by cell cycle phase, γH2AX increased the most in the G2/M 
phase of the cell cycle within treatment condition; however, substantial damage was 
observed in both the S- and G2/M cell cycle phases. This observed increase in DSBs 
may arise as a consequence of replication stress in S-phase, including reduced 
replication fork stability, which may be unresolved in G2/M. Furthermore, the removal 
of genomic uracil incorporated into DNA during replication by repair enzymes may 
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result the formation of DSBs, especially within fragile sites. In human fibroblasts, 
folate depletion increased DNA damage, but MTR loss-of-function did not. This 
observation may be explained by the fact that specific tissues exhibit varying degrees 
of responsiveness to vitamin B12 deficiency. De novo purine biosynthesis was not 
affected in fibroblasts, suggesting that the nucleus may be more sensitive to vitamin 
B12 depletion. An unexpected finding from this work revealed a striking increase in 
nuclear 5-formylTHF concentrations in HeLa cells. This observation is likely explained 
by the fact that 5-formylTHF is a tight-binding inhibitor of SHMT, and corroborates 
those previous findings indicating that SHMT does not provide the majority of one-
carbon units in dTMP, thereby suggesting a new role for 5-formylTHF in one-carbon 
metabolism.  
In summary, the findings from this work advance our understanding of the role 
of vitamin B12 in nuclear de novo dTMP biosynthesis, and provide a mechanism 
linking cytosolic vitamin B12 depletion to nuclear 5-methylTHF accumulation, 
depressed rates of de novo dTMP biosynthesis, and increased genome instability. 
Additionally, the findings presented here challenge our fundamental understanding of 
the 5-methylTHF trap and its role in genome instability and disease pathogenesis, as 
elevated folate did not exacerbate genome instability (γH2AX) or rates of NTDs under 
conditions of vitamin B12 deficiency. Furthermore, maternal vitamin B12 deficiency 
increased NTD incidence in mice with reductions in Shmt1 expression, but did not 
impair rates of fetal growth or maternal plasma homocysteine, suggesting that the 
nuclear compartment may be more sensitive to vitamin B12 deficiency than the 
cytosol. 
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Figure 4.1. Conceptual figure delineating the role of vitamin B12 deficiency in genome 
stability and disease pathogenesis. Vitamin B12 depletion, either by N2O treatment or 
MTR loss-of-function, traps intracellular folate as 5-methylTHF. In vitamin B12-
depleted HeLa cells, a nuclear trapping of 5-methylTHF occurs at the expense of 
THF, which leads to depressed rates of de novo dTMP biosynthesis and increased 
DNA damage (γH2AX). Both of the aforementioned outcomes are exacerbated by 
folate depletion. MTR loss-of-function fibroblasts exhibit decreased de novo dTMP 
biosynthesis capacity, but no impairments in de novo purine biosynthesis or 
increased γH2AX. Vitamin B12 deficiency causes NTDs in mouse embryos with 
reductions in Shmt1 expression independently of folate status. Gray text designates 
intracellular metabolites not directly measured. The blue transporters with a dashed 
arrow indicate the lack of mechanism for folate transport between the cytosol and 
nuclear compartments. Dashed arrows indicate the proposed sequence of events 
linking genome instability and NTD pathogenesis. Dashed boxes designate proposed 
events in the causal pathways underlying vitamin B12 depletion. Stars correspond to 
observations in vitamin B12-depleted HeLa cells; red stars indicate outcomes 
exacerbated by folate depletion. Black circles with open holes correspond to 
observations in MTR-loss-of-function fibroblasts. Closed black circles indicate vitamin 
B12-responsive outcomes that are not affected by folate status.   
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FUTURE WORK 
 
There are several findings raised by the results of this work that warrant 
further investigation and attention.  
The findings from Chapters 2 & 3 suggest that specific cell types exhibit 
increased sensitivity to vitamin B12 depletion. MTR-null fibroblasts exhibited impaired 
nuclear de novo dTMP biosynthesis and elevated intracellular 5-methylTHF, but did 
not demonstrate increased DNA damage in contrast to vitamin B12-depleted HeLa 
cells. Furthermore, neural tube closure was sensitive to maternal vitamin B12 
deficiency, which could not be rescued with folate. It remains to be determined why 
some cell types are more responsive to vitamin B12 deficiency than others. To further 
investigate this unresolved issue, it may be useful to develop specialized cell models 
of vitamin B12-responsive cell types that would enable more detailed analysis of the 
relationship between cellular vitamin B12 deficiency, nuclear 5-methylTHF 
accumulation, and other cellular processes. 
Additional findings from this work underscore a need to improve the 
development of functional biomarkers that link diet and nutrition to disease 
pathogenesis. The findings from both Chapters 2 & 3 indicate that the nucleus may 
be more sensitive to vitamin B12 deficiency than the cytosol. Several of the current 
biomarkers used to measure vitamin B12 status and function have limited sensitivity or 
account for activities in the cytosol, but do not adequately reflect functional 
consequences of deficiency in the nucleus. Two examples of such biomarkers that 
are commonly used include total serum vitamin B12 and homocysteine. Therefore, it 
may be a worthwhile endeavor to develop a new biomarker (or a set of biomarkers) 
used to assess genome stability. γH2AX is a biomarker with the potential to fulfill this 
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requirement, as it may be easily quantified in peripheral lymphocytes using a high-
throughput approach such as FACS. This approach would ideally be used in 
conjunction with more traditional measures of nutrient status. The development of 
functional biomarkers holds potential for significant implications when applied to a 
given population, as individuals have specific nutrient requirements that are modified 
by such factors as genetic variability, disease process, and medication intake, among 
others. 
